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Abstract  
 
Abstract  
Ischemic stroke is a leading cause of mortality, long-time disability and morbidity 
in the world. Currently, the only effective treatments are the intravenous 
thrombolytic therapy with tissue plasminogen activator (tPA) and the new 
emerging intra-arterial thrombectomies, which require to be administered in the 
hyperacute phase of stroke (<4.5 hours for tPA treatment and <6 hours for 
endovascular therapy). Therefore, it is necessary to investigate new therapies that 
could be used to treat a large number of patients in a later phase to repair and 
rewire the damaged tissue. One approach to achieve these objectives is to 
enhance vascular remodeling and neurogenesis in the ischemic brain.  
The aim of this thesis is to study the modulation of extracellular matrix 
metalloproteinase-13 (MMP-13) in brain injury and neurorepair and to investigate 
several MMPs as serving biomarkers to monitor motor and functional 
improvement during neurorehabilitation therapy. 
Using a distal middle cerebral artery occlusion model of ischemia in mice, we 
found that the modulation of MMP-13 is involved in ischemic damage and repair 
mechanisms. After ischemia-reperfusion, MMP-13 deficiency reduces infarct size, 
improves functional outcome and protects from hemorrhagic transformation, but 
impairs cortical tissue recovery by reducing proliferating neuroblast migration and 
vessel remodelling in a microenvironment with reduced trophic factors. At the 
same time MMP-13-silenced endothelial progenitor cells present an aberrant in 
vitro tubulogenesis function.  
As MMP-13 deficiency protects brain injury acutely and participates in post-stroke 
tissue recovery, this thesis also studies the temporal profile of plasma MMP-3, 
MMP-12 and MMP-13 during rehabilitation therapy to investigate their potential 
role as biomarkers of tissue recovery. Our results show that high levels of plasma 
MMP-13, as well as MMP-12, are strongly associated with stroke severity acutely, 
but not MMP-3. Interestingly, those patients with a better motor outcome during 
rehabilitation present elevated MMP-3 and decreased MMP-12/-13 levels. 
MMP-3 is closely associated with the better post-stroke motor recovery, indicating 
the potential as a biomarker of final functional improvement. These are important 
results that envision the use of biomarkers that could help to adjust, personalize 
and modulate neurorehabilitation therapies according to patients’ needs. 
In conclusion this thesis shows the role of MMPs in tissue injury and repair after 
stroke and the importance to monitor and modulate these proteases in favor of 
patients’ recovery.  
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Resum 
L'ictus isquèmic és una de les principals causes de mortalitat, discapacitat de llarg 
termini i de morbiditat al món. Actualment, els únics tractaments eficaços són el 
tractament trombolític intravenós amb activador del plasminogen tissular (tPA) i 
les novedoses trombectomies intra-arterials, que requereixen ser administrades 
en la fase hiperaguda de la malaltia (<4,5 hores per al tractament amb tPA i <6 
hores per les emergents la teràpies endovasculars). Per tant, és necessari 
investigar noves teràpies que podrien ser utilitzades per tractar un gran nombre 
de pacients en una fase posterior de la malaltia per reparar el teixit danyat. Alguns 
enfocaments terapèutics apunten que per assolir aquest objectiu és necessari 
potenciar la remodelació vascular i la neurogènesi en el cervell isquèmic.  
L'objectiu d'aquesta tesi és l'estudi de la modulació de la metaloproteinasa de 
matriu-13 (MMP-13) en la neurorreparación i el d’investigar diverses MMPs com a 
biomarcadors que serveixin per monitoritzar la millora de la funció motora durant 
la teràpia neuro-rehabilitadora. Utilitzant un model d’isquèmia cerebral per 
oclusió de l’arteria cerebral mitja en ratolins, es va trobar que expressió de la 
MMP-13 està implicada en el dany i en mecanismes de reparació post-isquèmia. 
Després de la isquèmia-reperfusió, la deficiència en MMP-13 redueix la mida de 
l'infart, millora l’estatus funcional en la fase més aguda i protegeix de l’aparició de 
transformacions hemorràgiques, però interfereix negativament en la recuperació 
del teixit cortical mitjançant la reducció en la migració neuroblast en proliferació, 
en el remodelat vascular i en un microambient amb factors tròfics reduïts. Al 
mateix temps les cèl·lules endotelials progenitores amb un silenciament transitori 
de l’expressió de MMP-13 presenten una funció aberrant en assajos de 
tubulogènesis, in vitro.  
Com que la deficiència de MMP-13 protegia del dany cerebral en el model animal 
d’isquèmia al temps que participava en la recuperació del teixit en fases de 
reparació, aquesta tesi també estudia el perfil temporal dels nivells plasmàtics de 
MMP-3, MMP-12 i MMP-13 durant la teràpia neuro-rehabilitadora per investigar 
el seu paper com a potencials biomarcadors del teixit en recuperació. Els nostres 
resultats mostren que alts nivells de plasma MMP-13, així com MMP-12, estan 
fortament associats amb la severitat i extensió de la isquèmia, però no els de 
MMP-3. Curiosament, els pacients amb un millor status en la funció motora 
durant la rehabilitació presenten els nivells més elevats de MMP-3 i reduïts de 
MMP-12 / -13. També, els valors de MMP-3 estan estretament associats amb la 
millor recuperació motora després de l'accident cerebrovascular, el que indica el 
seu potencial com a biomarcador de la millora en la funció motora. Aquests 
resultats són importants per imaginar el futur ús d'un biomarcador per tal de 
poder ajustar, personalitzar i modular teràpies de neuro-rehabilitació d'acord a les 
necessitats dels pacients. 
En conclusió aquesta tesi mostra el paper de les MMPs en el dany i reparació de 
teixits després de l'ictus isquèmic i ressalta la importància de monitoritzar i 
modular aquestes proteases en favor de la recuperació dels pacients. 
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1.  Introduction 
 
1.1 Ischemic Stroke 
Stroke is one of the leading causes of death and long-term disabilities worldwide. 
Every year, according to the World Health Organization (WHO), 15 million people 
suffer a stroke: nearly 5 million die and another 5 million are permanently disabled 
(www.who.org). Stroke occurs due to alterations with the blood supply to the brain: 
either the blood supply is blocked or a blood vessel within the brain ruptures. As a 
consequence of the sudden reduction of the physiological levels of blood flow to the 
brain, it results in a loss of oxygen and glucose followed by cell death, brain injury 
and the loss of neurological functions. 
This pathology is currently one of the most important health problems because its 
annual incidence is about 200 cases per 100,000 inhabitants and is the leading cause 
of death in women and second in men in Spain1, in addition to the major cause of 
long-term disability due to motor and sensory limitations. The main risk factors 
associated with stroke are hypertension, diabetes, atrial fibrillation, smoking and 
high cholesterol levels, being more prevalent after the age of 652. 
There are two types of stroke: ischemic strokes and hemorrhagic strokes (Figure 1), 
plus the transient ischemic attacks (TIAs) which last a relatively short time and 
usually causes no permanent injury to the brain (www.strokeassociation.org). In 
numbers, around 80% of all strokes belong to the ischemic subtype and the other 20% 
are caused by a hemorrhage.  
During an ischemic stroke, the blood supply to the brain decreases dramatically 
which usually happens when an artery is blocked by a blood clot or by the narrowing 
of the arteries. The part of brain that depends on the blood supply of the affected 
artery cannot sustain the normal cell metabolism due to the limited amount of 
oxygen and glucose, and the so called ischemic cascade is activated.  
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Figure 1.  Ischemic and hemorrhagic stroke in human brain. The figure is adapted from Heart & 
Stroke Foundation (www.heartandstroke.com)  
In a hemorrhagic stroke, an artery in the brain bursts: blood vessels inside the brain 
leak causing an intra-cerebral hemorrhage, while blooding under the outer 
meningeal coverings of the brain and into the fluid-filled space surrounding the brain 
leading to a subarachnoid hemorrhage. 
The TIA, also called as “mini-stroke", is often characterized as a “warning stroke” as a 
stroke finally occurs with most of those patients presenting a TIA symptoms in the 
following hours to months3. The reduction of blood flow in TIA is temporary which 
might not cause real cellular death and clinical symptoms usually last for a few 
minutes. However, patients that have suffered a TIA have more vascular events than 
those who did not fulfill the criteria of TIA at either 30 days or 90 days after the initial 
events4. 
The work presented in this thesis focuses on human ischemic stroke and an 
experimental model of this disease, therefore the remaining introduction text on 
mechanisms, treatments and molecular pathways of injury and repair will focus on 
this type of stroke. 
 
1.1.1 Ischemic Cascade and Neuroinflammation  
In ischemic stroke, the loss of blood supply into the brain results in a rapid loss of 
oxygen and glucose for the tissue, followed by the reduced cell viability or cell death 
accompanied by a destructured extracellular matrix that limits cell-cell interactions 
and the normal function of neuronal networks. 
As described below, all the process occurs in a cascade of pathological events: once 
the residual cerebral blood flow (rCBF) decreases below the 30% of the baseline 
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blood flow, neuronal dysfunction occurs. As the electrical function of the brain is 
intimately related to metabolism, a biochemical cascade is initiated, involving 
excitotoxicity, oxidative stress, inflammation and apoptosis5,6. Physiologically, the 
brain has a very high consumption of oxygen and glucose but little capability to store 
energy; hence the mitochondria play a key role during the metabolism in the brain. 
Once ischemia occurs, insufficient energy leads to membrane evoked potential 
cessation and cells depolarization, activating voltage/acid-sensing ion channels, 
leading to an imbalance in sodium and calcium levels (Figure 2). Calcium is thought 
to initiate a series of cytoplasmatic and nuclear events including targeting the 
intrinsic mechanical apoptosis7. Activation of calpains by increased calcium results in 
the cleavage of cell death related pro-apoptotic proteins. Actually, cells in ischemic 
core undergo necrosis and apoptosis: the initiation in ischemic core is thought to 
occur by an apoptotic pathway, but the severe decrease in energy level causes a shift 
from apoptosis toward secondary necrosis. At the same time, the energy-dependent 
processes such as presynaptic re-uptake of excitatory amino acids are impeded, 
which increase the accumulation of glutamate in the extracellular space and 
subsequent excitotoxicity. Induced cell damage occurs through necrotic and 
apoptotic cell death pathway after the triggering of glutamate receptors7. In parallel, 
mitochondria oxidative phosphorylation is also impaired due to the low levels of 
oxygen and glucose during ischemia, leading to the release of reactive oxygen 
radicals (or reactive oxygen species, ROS) and reactive nitrogen species (RNS) as well 
as increased anaerobic glycolysis6. ROS are considered as the main cause of 
membrane and fundamental cellular components damage8; and RNS act together 
with ROS forming highly reactive products which are capable of damaging lipids, 
proteins and DNA of the cells9. These direct damages on cellular membrane and 
other compartments, together with the indirect injuries from free radicals 
stimulating various cellular molecular pathways, lead to an abnormal accumulation 
of fluid within the brain parenchyma, which is called brain edema10. In addition, the 
overproduction of lactic acid from anaerobic glycolysis of the brain tissue causes 
neuron-toxic lactate accumulation, increasing the acute excitotoxicity phenomena 
which is also related to neuronal cell death11. 
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Figure 2.  Summary of pathological mechanisms in the ischemic brain. The figure is adapted from 
Dirnagl et al. 1999. 
However, the immediate permanent cell damage/death after the severe reduction of 
blood flow occurs mainly within the center of the ischemic territory, which is called 
the “ischemic core”. The peripheral hypoperfused tissue, where the blood flow is 
inadequate to support neuronal function, but just adequate to maintain cell viability, 
might be salvageable and is called “ischemic penumbra”12. If functional 
hypoperfusion is not confirmed by neuroimaging techniques, the territory 
surrounding the infarct core should be named peri-infarct boundary/tissue. With 
time going on, without effective vessel reperfusion, the ischemic threshold increases 
and the infarct core expands into the penumbra which might be accompanied by 
neurological deterioration of the patient. Brain cells, particularly the vulnerable 
neurons, undergo apoptosis which dominates cell death during this expansion13. As 
shown in the Figure 3, the initial ischemic infarct lesion expands to the ischemic 
hypoperfused penumbra leading an extensive damage after several hours.  
Timely effective vessel perfusion or potential neuroprotective interventions can 
reduce the spreading of depolarization and decrease the final infarct size7,14. The 
penumbra therefore is still the target for any hyperacute stroke therapy, and to 
identify the penumbra where the tissue is at risk and to apply in-time treatments 
would be of great importance15. In accordance with this dynamics of infarct 
expansion, the only effective treatments to avoid infarct expansion are the 
thrombolytic therapies with recombinant tissue plasminogen activator (t-PA) that 
should be administered within the first few hours16, and the new endovascular 
treatments which are also required to be performed within the first hours after 
stroke onset17,18,19.  
Introduction  
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Figure3. Magnetic resonance imaging (MRI) from an ischemic stroke patient. Perfusion-weighted 
imaging (PWI) indicating the large area of hypoperfusion at <6 hours after stroke onset (A). 
Diffusion-weighted imaging (DWI) showing the ischemic core at the same level of PWI at <6 hours 
after stroke onset (B) and at 48 hours (C). 
Finally, other mechanisms are also involved in the process of ischemic stroke at later 
time-points, such as inflammation. The calcium activated second-messenger systems, 
the increased free radicals as well as hypoxia itself trigger the expression of numbers 
of pro-inflammatory genes and activation of these molecules7. A rapid activation of 
resident inflammatory cells followed by the infiltration of circulating inflammatory 
cells in ischemic brain region has been documented20. Besides, the presence of 
necrotic cells in the tissue is also highly immunostimulatory. As a consequence, a 
large amount of inflammatory factors including cytokines, chemokines, matrix 
metalloproteinases (MMPs), adhesion molecules and ROS are released from injured 
tissue.  
Increased evidences indicate that inflammation contribute to ischemic brain damage 
and predominantly is deleterious in the early phase after ischemic stroke20; but 
growing evidence suggests that several neurological repair mechanisms might be 
coupled to the neuro-inflammation stimuli21,22. Major steps in the repair process 
include removal of dead cells, development of an anti-inflammatory micro 
environment, and generation of pro-survival factors fostering tissue reconstruction 
and repair23,24. Very few knowledge regarding to the participation of inflammation in 
brain tissue recovery is established, and even less in the long-term effects. This thesis 
will explore the role of some matrix metalloproteinases and growth factors in the 
delayed phase of ischemic damage.  
 
1.1.2 Ischemic Reperfusion Damage 
The reperfusion of vascular supply to an area temporarily deprived of blood flow is 
not always related to a final recovery of the tissue and good functional outcome, and 
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after stroke, there is usually some degree of reperfusion related to spontaneously 
reperfusion or treatment-induced recanalization of the occluded artery. 
Administration of t-PA 3 hours after clot-induced ischemia leads to effective 
reperfusion without affecting infarct volume or functional outcome at 24 hours after 
MCAo in mice25. Insufficient reperfusion or delayed recanalization is frequently 
associated with an exacerbation of tissue injury and profound tissue damage as 
explained in this section. During reperfusion after ischemia, both the innate and 
adaptive immune systems as well as the complement system, platelets and 
coagulation factors are involved26. Particularly during the early phase of reperfusion, 
innate immune cells dominate the cellular compositions of infiltrates such as resident 
microglia cells (the main innate immune cells in the brain), which response firstly to 
brain injury. Microglia exerting neurotoxic functions enhances the blood brain barrier 
(BBB) permeability by preceding the leukocyte infiltration. The BBB is constituted by 
vascular endothelial cells, basement membrane and pericytes, as well as the end-feet 
of astrocytes, by providing to the central nervous system a highly controlled cerebral 
homeostasis27. Both ischemia and reperfusion can destabilize and destroy the 
balance of this microenvironment by inducing the disruption of BBB integrity as 
proved in experimental models occluding the middle cerebral artery (MCA)28. But in 
transient ischemia models, the BBB disruption is typically more severe than that in 
permanent models, related to the sudden increased blood volume during 
reperfusion29. 
A major phenomenon during arterial reperfusion is the recirculation of oxygen which 
induces the overproduction of ROS and nitric oxide (NO) resulting in additional 
oxidative stress. On one hand cell death occurs through a number of mechanisms 
including both necrosis and apoptosis by mediating lipid peroxidation and 
desoxyribonucleic acid (DNA) damage induced by oxidative stress26. On the other 
hand impaired endothelial cell function occurs as a result of the excessive pericytes 
contraction and the exposure of the sub-endothelial extracellular matrix to blood 
flow, altering the permeability of BBB10. 
Subsequent hemorrhagic transformation (HT) of ischemic infarction is a 
well-recognized life-threatening consequence of ischemia followed by reperfusion. 
This phenomena occurs in around 10%-40% of ischemic stroke patients during 
ischemia-reperfusion, being the main complication of t-PA treatment30. Either early 
or delayed administration of t-PA cause different degrees of hemorrhage. From 
animal models of cerebral ischemia, the administration of t-PA 20 minutes after 
injury significantly increases the small HT within the infracted tissue (named 
hemorrhagic infarctions, HI), while 3 hours post-ischemia treatment increases the 
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occurrence of severe HT including type II HI and massive and expanding HT (named 
parenchymal hematomas, PH)25. In stroke patients, the presence of mild HI might not 
cause major neurological deterioration of the patient and it is considered a sign of 
benign reperfusion of the artery, whereas PH is usually associated with a worsening 
of the neurological status of the patient (especially those causing clinical symptoms 
in patients which represent 3-7 % of all HT events31). 
As mentioned, the disruption of the BBB and the continued endothelial damage 
mediated by free radicals contribute to the appearance of HT in ischemic-reperfusion 
tissue. However, the mechanism of early HT (within 18-24 hours after stroke onset) is 
different from the delayed HT (beyond 18-24 hours). The early HT is thought to relate 
to leukocytes-derived MMPs damaging the BBB, while the delayed HT associated 
with ischemia activated brain derived proteases, neuroinflammation and other 
factors30. Other consequences of the disruption of BBB are the aggravation of tissue 
swelling, capillary plugging, platelet adhesion and thrombosis, being those correlated 
with enhanced stroke damage by the communication within neurovascular units32. 
 
1.1.3 Animal Models for Ischemic Stroke  
Animal models of cerebral ischemia are effective experimental tools to better 
understand the pathological mechanisms of ischemic injury and to test potential 
therapeutic interventions in preclinical trials. As different types of stroke occur in 
human associated to different mechanisms, etiologies and outcomes, there is no 
single universal animal model for all forms of human stroke33.  
There are multiple animal models of focal cerebral ischemia involving both 
permanent and transient middle cerebral artery occlusion (MCAo) mostly applied in 
rodents due to ethical and economic reasons. Intra-luminal filament models are 
well-established methods and widely considered adequate to reproduce primary 
ischemic insult and subsequent cell death, glial activation, blood brain barrier 
damage, among other pathological mechanisms34,35. But this model presents high 
premature mortality rates due to the large ischemic lesion affecting both the 
striatum and the cortex (Figure 4), produced by a proximal occlusion of the MCA, 
which might be not suitable for long-term neurorepair or safety studies. On the other 
hand, a different size of infarct lesion between young and aged mice is found only in 
distal MCAo models but not proximal, indicating that small infarct lesions are more 
willing to be modulated by neurogenesis-involved mechanisms36. Besides, many 
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human strokes are small in size and the occlusion of distal MCA is the most common 
reason for human ischemic stroke37,38. In experimental models, distal MCAo can be 
induced by permanent electrocoagulation, vessel contraction (endothelin injection) 
or by a transient ligation/compression of the distal branch of the MCA generating a 
cortical infarction. Among other described methods39, the embolic and 
thromboembolic models are ideal methods to mimic the clinical ischemic stroke, and 
offer the potential to evaluate thrombolytic agents or combination therapies40,41. 
However, these models induce occlusions without control of exact reperfusion time 
and degree. A focal cerebral ischemia model produced by ferric chloride 
(FeCl3)-induced thrombus formation has been described in a previous publication
42. 
This model holds the advantage of low mortality, easy to perform and no additional 
trauma to the brain tissue. However, reperfusion is still hard to achieve and to 
control. Finally, a new reproducible method for distal focal cerebral ischemia in mice 
with reperfusion by the distal MCA compression was developed in our lab, based on 
the previous mechanical methods43. The present model holds the advantages of 
minimal damage to the vessel and underlying tissue, high reproducibility and low 
mortality, at the same time that allows controlled tissue reperfusion. Mortality is a 
critical parameter in experimental studies as low mortality rates are important to 
reduce the number of animals and avoid selective bias of the obtained results. This 
model together with the distal electro-coagulation of the MCA has been used as the 
experimental ischemia model in this thesis. 
 
Figure 4.  2,3,5-Triphenyltetrazolium chloride (TTC) stained brain sections non-viable tissue (white 
areas) after different experimental models of stroke in rodents. 
 
1.1.4 The Neurovascular Unit  
Although the mechanisms of single cell death have been studied deeply, the 
mechanism by which the whole BBB responds to ischemia-reperfusion in the injury 
and recovery phases of stroke are still under investigation. The concept of 
neurovascular unit was suggested more than one decade ago, and refers to the 
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interconnection among cerebral endothelial cells, astrocytes, adjacent neurons and 
the extracellular matrix together with the circulating elements in the blood stream2. 
It is a functional unit revealing the complex inter-relationships among all the brain 
cells and tissue environment related to cerebral diseases. Neurons, as the core 
functional cell in the brain tissue, play a dominant role during the development of 
neurological dysfunction in cerebral ischemia; however, neurons are not the only 
target influencing tissue outcome in ischemia-reperfusion damage. The 
neurovascular unit emphasizes the dynamics communication of vascular, cellular and 
matrix signaling in the brain (Figure 5).  
 
Figure 5.  Organization of the capillary neurovascular unit. The figure is adapted from Abbott et al. 
2010. 
An example is the disruption of the BBB which is crucially dependent on 
endothelial-astrocyte-matrix interactions which are related to the tight junctions and 
basal lamina integrity. Endothelial cells, the main source of reactive radical species 
after ischemia-reperfusion, contribute to the BBB connection via adherent and tight 
junctions to form a physical barrier together with pericytes. Astrocytic end-feed 
wraps around capillary endothelial cells regulate cerebral capillary blood flow as well 
as the permeability. We now know that the endothelial cells and astrocytes engage in 
a complex cross talk to regulate each other’s function44. Extracellular matrix proteins 
contribute to the structural formation of basal lamina that connects to endothelial 
cells by the cell-matrix interaction. When the BBB is disrupted by ischemia, injury to 
the microvasculature can lead to injuries to neuron in the same territory45. In this 
context, ischemic brain damage is not the only trigger of neuronal cell death, also the 
local environment which influences surrounding cells, allowing neurons to survive or 
to die.  
The function of this neurovascular unit in the cerebral micro environment is also 
related to the “cross-talk” among cells46. Increased studies have documented that 
various factors mediate the interaction both in health and disease including 
neurotransmitters and inflammatory mediators47. For example, during synaptic 
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activities, being initiated by neurons, both neurons and astrocytes release 
neurotransmitters, including acetylcholine, glutamate and γ-Aminobutyric acid 
(GABA) directly or indirectly stimulating the production of vasodilators to control the 
vasodilatation of arteries at the site of activation44.   
But the homeostasis of the neurovascular unit is also important during stroke 
recovery. The expression of reactive astroglia expressed glutamate transporter is 
positive related with the neurological score during day 1-3 after ischemia-reperfusion 
in rats48. Post-stroke injection of antagonist of glia-specific glutamate transporter 
significantly changes the number of neurons responding to forelimb stimulation after 
stroke in mice49.  
 
1.1.5 Angio-neurogenesis 
In spite of the neurological dysfunctions caused by stroke are a consequence of 
tissue and cell damage, surviving patients undergo some spontaneous recovery by 
triggering self-repair processes (Figure 6)50,51. However these are limited in terms of 
tissue repair.  
Recovery could therefore occur by multiple mechanisms52,53:  
1) Restoration of damaged neurons and their function;  
2) Remodeling the structure or function of the remained undamaged neural cells 
(so called “neuroplasticity”); 
3) Formation of new functional neurons from pre-existing progenitors. 
 
Figure 6. Representation of injury and spontaneous repair mechanisms triggered by stroke. The 
figure is adapted from E Lo et al, 2008. 
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The formation of new functional neurons is called neurogenesis.  
Physiologically, newborn neurons generated from the subventricular zone (SVZ) 
migrate to olfactory regions whereas those neurons generated from subgranular 
zone (SGZ) migrate to hippocampus54. It has been reported that after cerebral 
ischemia, SVZ-derived neural precursor cells have the capability to respond to the 
insult and migrate toward to the lesion area to produce new cells replacing the 
damaged cells in rodents55,56, and this migration and proliferation was also observed 
in human in response to ischemic stroke57. This generation of newborn neurons after 
stroke is proven associated with functional recovery by integrating into the existed 
neuronal network58.  However, the sustained functional improvement is obviously 
earlier than the maturation of these new generated neurons59. Besides, the majority 
of these newborn cells die from apoptosis in a few days, and the rate of 
differentiation is low55,60,61. This mismatch supports the hypothesis that neurogenesis 
induced-recovery is mediated by mechanisms other than directly neuronal 
replacement, possibly through local growth factors mediated functional restoration 
in the peri-infarct tissue59. 
As detailed in previous sections, ischemia initiates inflammation, increases 
microvascular permeability and might cause hemorrhage, which does not only 
influence neurons in the first stage but also other glial cells supporting neurons and 
the microvessels that supply oxygen and glucose. The concept of the neurovascular 
unit proposes that, injury to any part of the unit affects the other components 
unbalancing the neurovascular homeostasis that allows the physiological 
environment of the brain. In this regard, the most classical view of neurorepair as the 
replacement of dying neurons has changed in the last decades for a more global 
understanding of the brain, including other cell types (glial cells, inflammatory cells 
and stem/progenitor cells) but also the extracellular matrix and their interactions. 
Therefore endogenous mechanisms of neurorepair include angio-vasculogenesis 
(formation of new blood vessels), gliogenesis (formation of new glial cells), 
neurogenesis (formation of new neurons), re-myelination (new myelin sheaths on 
demyelinated axons), among others. Part of this thesis focuses on angiogenesis as a 
key mechanism to modulate during stroke repair.  
Classically, the formation of new blood vessels was thought to be mediated 
exclusively by embryogenic vasculogenesis, followed by the sprouting of endothelial 
cells from pre-existing vessels during angiogenesis62. However, this dogma was 
overturned with the discovery of bone marrow-derived CD34+ cells with endothelial 
characteristics and circulating in adult human blood63. These cells, referred as 
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endothelial progenitor cells (EPCs), are capable of differentiating ex vivo into 
endothelial-phenotyped cells, and represent a new model for endothelial 
regeneration and vessel repair. In this context, EPCs have been shown to be highly 
migratory to ischemic areas and a powerful therapeutic potential by directly 
enhancing angiogenesis or by forming new vessels through vasculogenesis64,65. In 
addition to the therapeutic interest of endothelial progenitors for vascular 
regeneration, it is extremely important to know more on the role played by the 
growth factors secreted by these cells which enrich the so called neurovascular 
niche. 
It is known that angiogenesis-related genes such as vascular endothelial growth 
factor (VEGF) are up-regulated as soon as 1 hour after ischemia onset; and the 
post-stroke vascular formation in the peri-infarct area is also involved in the process 
of tissue recovery, involving angiopoietins (Ang) up to 21 days after ischemia60,66,67. 
But angiogenesis activation after cerebral ischemia does not occur alone, it is actually 
coupled to neuroblast cell migration from the SVZ58. In this context, the role might be 
as important as the one played by neural precursor cells. 
The so called neurovascular niche defines these complex mechanisms of crosstalk 
between cerebral endothelium and neural precursors under ongoing neurogenesis. 
Stroke changes the cellular environment in the peri-infarct area by forming a unique 
neurovascular niche, in which angiogenesis and neurogenesis are linked through 
specific vascular factors and chemokins59. Apart from the VEGF, the cytokine stromal 
derived factor-1 (SDF-1), also named as C-X-C motif chemokine 12 (CXCL12), is 
another important molecular playing a central role in the post-stroke neurovascular 
niche. The SDF-1 and its receptor C-X-C motif chemokine receptor type 4 (CXCR-4) 
participate in a variety of physiological and pathological processes including 
angiogenesis and neurogenesis through mediating the proliferation of neurogenitors, 
regulating the migration, differentiation, as well as functional integration of newborn 
neurons into existing networks68. We have also learnt that cerebral vessels express 
SDF-1 days after cerebral ischemia in peri-infarct areas where neurogenesis occurs, 
and the specific blockage of angiogenesis by the administration of specific inhibitors 
(such as endostatin) also blocks endogenous post-stroke neurogenesis from the 
SVZ59.  
As we will see in this thesis, several therapeutic approaches under investigation have 
their target on the modulation and enhancement of these mechanisms that 
participate in neurological repair after stroke.  
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1.2 Matrix Metalloproteinases 
The degradation of extracellular matrix substrates plays a crucial role in both 
ischemia induced disruptions of the BBB as well as in cell proliferation and cell 
migration during tissue repair. Together with adamalysin-like metalloproteinases with 
thrombospondin motifs (ADAMTSs), MMPs are capable to degrade the extracellular 
matrix, plating important roles in many physiopathological processes69,70. MMPs are 
a family of zinc-dependent proteinases, involved in the degradation and remodeling 
of extravascular matrix and vascular compartment due to their capability to 
degradation of basal lamina and extracellular matrix components. This protease 
expression and activation occurs in physiological conditions during the normal 
homeostasis of the extracellular matrix but the dysregulation of some MMPs also 
participates in processes of tissue injury and repair71. Despite MMPs have been 
considered for a long time to be the prototypic matrix-degrading proteases, in recent 
years and with the application of engineered genetic models, they have been shown 
functions more as processing enzymes that control numerous, diverse cell processes. 
Indeed, via cleavage of cytokines, chemokines, antimicrobial peptides, and cell 
surface proteins, MMP proteolysis affects critical regulatory functions related to 
immunity, tissue repair, differentiation, and cell transformation72.  
There are four primary subgroups of MMPs on the premise of the structure domain: 
collagenases (MMP-1, -8 and -13), gelatinases (MMP-2 and -9), stromelysins (MMP-3, 
-10 and -11) and others not belonging to any of them73. Physiologically, most of the 
MMPs are synthesized as inactive forms (also named pro-forms), and their activity is 
strictly controlled by gene transcription which is mediated by variety of inflammatory 
cytokines, hormones and growth factors74. However, MMPs are also regulated at 
post-transcriptional level through an activation mechanism: the activated MMPs can 
participate in processing the activation of other MMPs, and the irreversible MMPs’ 
activation can be blocked by tissue inhibitors of metalloproteinase (TIMP)75. 
Uncontrolled MMP activity has been described in several diseases and many 
pathological processes including cerebral ischemia are associated to an increase in 
MMP levels and activity related to the degradation of proteins such as laminin, 
fibronectin, collagen, proteoglycans, and others. 
Different investigators have suggested that the upregulation of MMPs such as 
MMP-2, MMP-3 and MMP-9 contribute to infarct extension and BBB breakdown 
after stroke76,77,78, and blood levels of some MMPs can also be easily monitored as 
potential biomarkers of brain tissue damage and/or neurological outcome79,80. Also, 
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brain MMP-9 is up-regulated in ischemic brain tissue related to vessel disruption and 
blood extravasation in human samples81,82,83, and the gene or pharmacologic 
inihibition of MMP-9 has demonstrated to protect the brain from cerebral ischemia 
in preclinical models84,85,86. A list of the putative role of most relevant MMPs related 
to ischemic stroke has already been summarized by some researchers (Table 1)87.  
Table 1. MMPs and their putative roles in ischemic stroke. (The table is adapted from Lakhan et al. 
2013)  
MMP Putative roles in ischemic stroke 
MMP-2    
(gelatinase A) 
Attacks major components of the basal lamina around the cerebral blood vessels 
including collagen IV, lamina and fibronectin. May contribute to infarction and 
hemorrhagic volume.  
MMP-3 
(stromelysin-1) 
Degrades the extracellular matrix proteins fibronectin, denatures collagen, 
lamina and proteoglycans. Plays a key role in the initial opening of the BBB after 
stroke and the development of hemorrhagic transformation, particularly with 
tPA treatment. Promotes remyelination and the chemokines induced neural 
progenitor cells’ differentiation and migration.  
MMP-8 
(collagenase-2) 
Preferentially cleaves collagen I. Unregulated in infracted tissue but studies are 
limited.  
MMP-9    
(gelatinase B) 
Attacks major components of the basal lamina including collagen IV, lamina and 
fibronectin. Plays a key role in the delayed opening of the BBB especially in the 
states of systematic inflammation, related to hemorrhagic transformation 
particularly with tPA treatment. Is involved in the neurovascular remodeling by 
mobilizing VEGF, myelin reformation and EPCs angiogenic function; promotes 
the chemokines induced neural progenitor cells’ differentiation and migration.  
MMP-12 
(macrophage 
metalloelastase) 
Degrades soluble and insoluble elastin. Contributes to the acute brain damage 
may related to the activation of MMP-9.  
MMP-13 
(collagenase-3) 
Preferentially cleaves collagen II. Upregulated in infracted tissue but its study is 
limited. 
 
At the beginning of this section we have pointed out that these proteases might also 
contribute to beneficial remodeling during stroke recovery. In this regard, early 
studies already shown that MMPs are expressed during development and contribute 
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to morphogenesis of the CNS88. They are also related to neurogenesis mediating the 
differentiation and chemokine-induced cell migration of adult neural progenitor 
cells89. MMPs may also modulate bioavailable levels of various growth factors (such 
as VEGF by MMP-9 actions) by processing pro-form precursors or by liberating active 
molecules from matrix-hidden compartments90. After stroke, newly born neuroblasts 
migrate from the SVZ to peri-infarct cortex, and increased vascular remodeling is also 
found in this area91,92. At 2 weeks after cerebral ischemia in mice, MMP-9 is 
enhanced in the SVZ and co-localized with BrdU-labeled cells and neuroblasts 
whereas the pharmacological inhibition of MMPs reduces the extension of 
neuroblast signals that extend from the SVZ into the damaged striatum and 
post-stroke angiogenesis impairing functional recovery93,94. As we will better describe 
latter, our group has recently described the central role of MMP-9 in vascular 
remodeling mediated by endothelial progenitor cells in the context of cerebral 
ischemia both in vitro and in vivo95,96.  
Regarding MMP-13 (collagenase-3), the dominant collagenase, the current 
knowledge comes from cancer, bone-related diseases and re-epithelialazation of the 
skin during wound healing97,98,99, but limited studies have been published related to 
the role of this protease in stroke disease. A few studies from our group and others 
have shown an increased expression of MMP-13 in infarct areas compared to healthy 
control human tissue81, located in neurons as well as in glial cells in ischemic 
models100,101. Also a high level of MMP-13 in blood is related to the early lesion 
expansion in stroke patients who received thrombolytic therapy102. The modulation 
of MMP-13 during the delayed phases of stroke is still unknown. 
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1.3 Treatments for Ischemic beyond t-PA 
Although the understanding of post-ischemic injury is still limited, new insights of 
therapeutic approaches are accumulating. Being the blockage of a cerebral artery by 
a blood clot, the pathological cause of ischemic stroke, the recanalization therapy to 
reperfuse the artery and recover the cerebral blood flow is still the only effective 
treatment to reduce tissue injury and improve neurological outcome. The 
intravenous thrombolysis with t-PA is still the mainstay of acute ischemic stroke 
management for the patients within 4.5 hours from symptom onset, being a 
standard therapy for those patients with moderately severe symptoms younger than 
80 years old and without contraindications for the medication16,103. The new 
emerging effective intra-arterial therapy using stent retrievers also requires to be 
applied within the first 6 hours17,103. As both of these two successful treatments 
require rapid intervention, only 5% to 7% of patients are treated with t-PA along with 
1% to 2% benefit from intra-arterial therapy, whereas the majority of patients do not 
meet criteria to receive these available reperfusion therapies. In this context, the 
development of neurorestorative and neurorepair therapies available for the vast 
majority of patients to improve neurological deficits after ischemic stroke is a great 
challenge. 
As mentioned, the spontaneous brain neurorepair is limited in efficacy and 
heterogeneous among patients. Strategies to enhance the endogenous restorative 
mechanisms of recovery are sought as stroke treatments. The central goal of these 
potential therapies should be to prevent further damage during the delayed phases 
of ischemia minimizing the damaging molecular events and cell death, at the same 
time that new opportunities of tissue recovery should be stimulated to remodel and 
recover the affected tissue (Figure 6). 
 
Figure 6. Spectrum of therapies for ischemic stroke according to the chronical sequence of 
Introduction  
17 
 
mechanisms of injury and repair. The figure is adapted from Zaleska et al. 2009. 
 
1.3.1 Neurorehabilitation after Stroke  
Despite important advances in acute stroke management in the last two decades 
(the management of patients in stroke units, the thrombolytic therapy or the new 
emerging endovascular treatments), each year about five million people survive a 
stroke worldwide with some disabilities that limit their independence for daily 
activities (www.who.int). This fact also carries an enormous socio-economic burden 
estimated at ‎€196 billion every year for the countries of the European Union 
(www.ehnheart.org). For those patients the only approved treatment during the 
sub-acute and chronic phases of the disease is neurorehabilitation to recover the 
impaired or lost neurological functions with the objective of improving their 
independency status and quality of life104,105.  
During rehabilitation, the improved outcome in patients is the result of early 
mobilization, rehabilitation intensity and other measures to prevent/treat medical 
and psychological complications, altogether being performed by an inter-disciplinary 
team, and also according to spontaneous individual and heterogeneous response to 
therapy106,107. And the ultimate goal of any rehabilitation therapy is to reach the 
maximum recovery of the impaired function in an effort to reduce disability and 
achieve functional independence for daily activities of the patient. However, the 
recovery of other non-motor functions (the executive function, attention, memory, 
etc.) is also the subject for rehabilitation therapies. 
Importantly, for the overall rehabilitation process it is very important to assess 
patient's neurological function, independence and quality of life after stroke. The 
impact of the disease can be measured using certain scales which also allow to 
monitor and to evaluate the impact of the received therapies. As there is no 
consensus on the use of a single scale that can measure all the affected aspects of 
disability after stroke, many scales are commonly used in the clinical practice and in 
clinical trials to evaluate the therapeutic potential of a particular therapy105,108 
despite certain limitations in their sensitivity, specificity and reliability among 
observers. It is therefore common to use a battery of scales to assess neurological 
deterioration or improvement of the patient’s function in rehabilitation 
therapy104,109,110. Table 2 shows a summary of the most used scales during 
rehabilitation therapy after stroke. 
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Table 2. Summary of the most used tests/ scales to measure the outcome in stroke rehabilitation. 
Measures  Description  
NIH Stroke Scale (NIHSS)    A quantitative measure of the severity of symptoms/ 
neurological deficit associated with cerebral infarcts. 
Fugl-Meyer Assessment (FMA) A disease-specific impairment index to assess motor function, 
balance, sensation qualities and joint function.  
Medical Research Council (MRC) To exam the peripheral nerve lesions by testing the muscle 
strength. 
mRankin A global outcomes rating scale for daily activity/disability. 
Barthel Index (BI) The most widely used measure of functional disability. 
Functional Ambulation Categories 
(FAC) 
To assess ambulation capability. 
Chedoke Arm and Hand Activity 
Inventory (CAHAI) 
A functional assessment for the upper-limb recovery.  
10 meters’ Walking A sub maximal test to assess functional capability. 
Stroke Specific Quality of Life Scale 
(SS-QOL) 
To assess health-related quality of life.  
 
1.3.2 Neurorehabilitation and Tissue Repair 
From a biological perspective, we know that neurorehabilitation enhances different 
aspects of brain plasticity such as axonal remodeling, cell genesis, angiogenesis or 
synaptogenesis111, which could be patient-dependent, and the biological 
mechanisms responsible for these individual responses to treatment are still being 
investigated.  
Fortunately, in some patients the recovery of the neurological function occurs 
spontaneously after stroke and in others it is achieved with some types of 
rehabilitation therapy up to 6 months or 1 year after stroke109. The spontaneous 
recovery is related to brain plasticity and is also observed in animal models of stroke 
being particularly significant in mice112. In this sense, several mechanisms have been 
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described to be related to functional recovery such as: the activation, proliferation 
and migration of endothelial/neural progenitor cells, changes in existing neural 
pathways, the compensation phenomena and also an increased neuroanatomical 
plasticity leading to the formation of new neuronal connections111. Today we know 
that the brain repair/regeneration process occurs from outlying areas of the infarct 
core, where these stem/progenitor cells arrive to replace or to provide trophic 
support to the pre-existing cells traffic113.  
Another important aspect during rehabilitation is the convenience to have 
biomarkers that could support an accurate and individual prognosis of stroke 
recovery during the rehabilitation program, which would help to decide on the 
intensity, type or duration of the rehabilitation programs108.  
However, very few studies have investigated the use of biomarkers during 
rehabilitation therapy for post-stroke recovery linked the progress of functional 
rehabilitation (determined by specific scales). In this regard the levels of certain 
cytokines such as interleukins (IL), tumor necrosis factor alpha (TNF-alpha) and 
adhesion molecules have been monitored in patients with a first-ever stroke under 
rehabilitation therapy compared with a control population showing an increase in 
IL-6 and TNF-alpha in stroke patients versus controls, and a negative association of 
IL-1-alpha, IL-8 or TNF-alpha with the Barthel Index114. But the study only covers the 
first two weeks after stroke. More recently, Blicher and colleagues have studied the 
neurotransmitter GABA by magnetic resonance spectroscopy in relation to motor 
function after 2 weeks of constrained-induced movement therapy showing an 
association between motor improvement and the magnitude of the GABA/creatine 
ratio115. Finally a recent study has reported the use of 8-hydroxy-2’-deoxyguanosine 
(8-OHdG), a sensitive marker for DNA damage that is detectable in urine samples, in 
a cohort of stroke patients undergoing rehabilitation therapy reporting a negative 
correlation between FMA scores and 8-OHdG level after rehabilitation treatment and 
lower levels of baseline 8-OHdG in patients that exhibited more improvement in 
motor function, suggesting the use of 8-OHdG as a biomarker of stroke recovery116. 
Given the complexity of the CNS responses to cerebral ischemia and the role of 
neural plasticity in tissue regeneration and functional recovery, it is likely that future 
rehabilitation treatments will be combined with pharmacological/biological therapies 
to enhance certain molecular pathways. In this context, to identify the key molecules 
responsible for these tissue regeneration mechanisms will be of great importance to 
influence the natural history of the disease. Part of this thesis focuses on the study of 
matrix metalloproteinases during intensive rehabilitation therapy related to the 
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motor/functional improvement achieved at different moments of the rehabilitation 
program. 
 
1.3.3 Cell-based Therapy 
Cell-based therapies have been demonstrated to be an effective approach for brain 
repair by enhancing the endogenous restorative mechanisms of recovery in 
preclinical models of stroke117, and some of them are being tested in the clinical trials 
(/www.clinicaltrials.gov). Most of these treatments do not aim to replace the 
damaged cells, but to remodel the total system by modifying the cerebral 
microenvironments, thereby enhancing the neuroplasticity through angiogenesis, 
neurogenesis, oligodendrogenesis or synaptogenesis. Multiple stem/progenitor cells 
have been tested as potential sources for cell-based therapies including neural stem 
cells, mesenchymal stem cells or bone marrow-derived cells proving their efficacy in 
animal models of stroke improving the functional recovery or reducing brain 
lesions118. However, there are several types of stem cells, and to identify which 
subtype is the best one contributing to the robust therapeutic improvement is still a 
challenge. Moreover, there is still no consensus regarding to issues related to the 
therapy such as how long will these cells survive, what time point is the best one to 
administer those treatments or which group of patients are expected to benefit most 
from these therapies119. 
As the main goal of cell-based therapy is to create a favorable microenvironment for 
tissue repair in the desired peri-infarct area, and angiogenesis plays a pivotal role 
during this process, EPCs have attracted increasing attention in the last years. EPCs 
were firstly identified as bone marrow derived cells responsible for the postnatal 
vasculogenesis both in physiological and pathological neovascularization, circulating 
in adult humans120,63. After ischemic damage, EPCs mobilize from bone marrow to 
the peripheral blood; home to the sites of vascular remodeling in the brain where 
they differentiate into mature endothelial cells and/or regulate preexisting 
endothelial cells via paracrine or juxtacrine signals121, contributing to neurovascular 
repair after stroke. Importantly, the number and function of EPCs could be 
modulated after stroke to improve cell-based tehrapies122. In this line our group has 
demonstrated that the genetic or pharmacological inhibition of MMP-9 diminished 
the pro-angiogenic actions of EPCs95, and that the post-stroke neurovascular niche 
requires MMP-9 for an appropriate vascular remodeling and pro-angiogenic action of 
an EPC-based therapy in a mouse model of stroke96. These studies highlight the role 
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of MMPs in post-stroke neurorepair cell-based therapies.  
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2.  Objectives  
 
 
The main objectives of this PhD thesis are:  
1) To conduct a systematic review of the literature studying Endothelial Progenitor 
Cells role in vascular remodeling and cell-cell interactions related to 
neurorepair after stroke.  
2) To determine the role of MMP-13 both in brain injury after cerebral ischemia 
and in post-stroke neurorepair mechanisms such as angiogenesis and 
neurogenesis. 
3) To identify the temporal profile of MMP-3, MMP-12 and MMP-13 serving as 
biomarkers of recovery during intensive rehabilitation therapy after ischemic 
stroke.  
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ABSTRACT 
New neuroreparative and neuroprotective 
therapies are being sought to treat stroke 
patients. One approach is the remodeling of 
extracellular matrix, which participates in both 
brain injury and neurovascular repair when 
matrix metalloproteinases (MMPs) are thought 
to be key players. Our aim was to investigate the 
role of MMP-13 (collagenase-3) in the acute (24 
hours and 3 days) and delayed (2 weeks) phases 
of stroke. Permanent and transient cerebral 
ischemia models involving the cortex were 
induced in MMP-13 knock-out (KO) and wild-type 
(WT) mice. In the transient model, MMP-13 
deficiency reduced the amount of TTC-stained 
infarct tissue, reduced hemorrhagic events and 
improved functional outcomes (p<0.01). At two 
weeks, normal neuroblast (DCX+) migration from 
the subventricular zone toward the peri-infarct 
area was observed. However, MMP-13 deficiency 
significantly reduced the number of newborn 
neuroblasts (DCX+/BrdU+) in the cortical 
peri-infarct area (p<0.01). This result occurred in 
parallel with aberrant cortical vascular 
remodeling: post-stroke peri-infarct vessel 
density increased in the WT mice (p<0.01) but 
this increase was blocked in the MMP-13 KO 
mice. Prior to these vascular alterations, the 
levels of pro-angiogenic factors, including G-CSF, 
VEGF-A and angiopoietin-2, were lower in the 
ischemic cortex of MMP-13 KO mice than in WT 
mice (p<0.05). In vitro, gene-silencing of MMP-13 
in endothelial progenitor cells (EPCs) confirmed 
the reduced ability of these cells to build 
tubulogenic networks in MatrigelTM substrate. 
Together, our results indicate that MMP-13 is a 
central protease in infarct development and 
cortical remodeling during post-stroke 
neurorepair, which is critical for optimal 
angiogenic and neurogenic responses. 
KEY WORDS: cerebral ischemia, MMP-13, 
angiogenesis, neurorepair, neurogenesis 
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INTRODUCTION 
Stroke is one of the most common causes of 
death and disability worldwide. Our investigation 
focused on ischemic stroke, which occurs when 
blood flow into the brain is interrupted by an 
artery occlusion. Recombinant tissue 
plasminogen activator (rtPA) and mechanical 
thrombectomy interventions are the only 
therapies that have shown efficacy, but they 
must be administered within a short therapeutic 
time window (Hacke et al., 2008; Lees et al., 2010, 
Jovin et al., 2015). New post-stroke therapies are 
therefore needed to diminish damaging 
molecular events and cellular death, which are 
responsible for further damage, at the same time 
that new opportunities to recover tissue are 
investigated. Of special interest are treatments 
that induce neurological repair with the aim of 
improving functional outcomes and rescuing the 
limited capability the damaged brain has to 
self-recover, with the potential to be 
administered in a wider therapeutic time window 
(Zhang and Chopp, 2009). One approach to 
potentiating neurological repair is to target 
angioneurogenesis, which is the formation of 
new vessels and neural cells. Adult neurogenesis 
occurs primarily in the subventricular zone (SVZ) 
and the subgranular zone (SGZ), from which 
newly born neural cells migrate to the olfactory 
bulb or to the dentate gyrus under physiological 
conditions (Ming and Song, 2011). However, 
ischemic stroke alters this pattern of 
neurogenesis and stimulates neuronal cells to 
migrate toward the damaged area (Ohab and 
Carmichael, 2008). In this environment, the 
neurovascular niche has been described as 
linking angiogenesis and neurogenesis, 
demonstrating that, after stroke, neurogenesis 
occurs following angiogenesis in the peri-infarct 
areas and showing strong support for the idea 
that trophic factors are secreted by endothelial 
cells (Ohab et al., 2006) and glial cells (Hayakawa 
et al., 2014). 
In this context, extracellular matrix remodeling is 
a key step in angiogenesis and neurogenesis 
during which matrix degradation is required to 
allow cell migration and capillary reorganization 
(Bovetti et al., 2007; Senger and Davis, 2011). 
Matrix metalloproteinases (MMPs), a family of 
zinc-dependent enzymes, are involved in the 
regulation of the composition of the cell-matrix. 
Interestingly, some MMPs have been described 
not only as the focus of many neuroprotective 
pre-clinical therapies aimed at protecting the 
brain during the acute phase of stroke but also as 
playing multiphasic roles, including roles in 
neurovascular remodeling during neurological 
recovery in rodent models of stroke (Zhao et al., 
2006; Rosell and Lo, 2008). Among all the MMPs, 
the role of MMP-13 (also named collagenase-3) 
in neurorepair and vascular remodeling is 
unknown. As a major collagenase, MMP-13 
mainly cleaves collagen II, shows the highest 
gelatinase activity among the collagenases 
(Knäuper et al., 1996; 1997) and has a central 
position in the activation of other MMPs, 
through which it plays a key role in angiogenesis 
and the re-epithelialization of the skin during 
wound healing (Hattori et al., 2009). In the 
context of cerebral ischemia, increased 
expression of MMP-13 has been described in rat 
neurons, where it peaks on day 7 after ischemia 
(Nagel et al., 2005). Previous results from our 
group showed that high blood levels of MMP-13 
were associated with lesion expansion in the 
acute phase of stroke (Rosell et al., 2005), 
whereas nuclear MMP-13 was found to be 
expressed in neurons and glial supporting cells in 
human and rodent ischemic brain tissue 
(Cuadrado et al., 2009a). In the present study, we 
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aimed to determine whether MMP-13 could 
acutely modulate neuroprotective and 
neurological repair functions during the recovery 
phase of ischemia, and we focused our interest 
on post-stroke vascular remodeling. For this 
purpose, both permanent and transient ischemic 
stroke models were induced in MMP-13 deficient 
mice, demonstrating that MMP-13 is involved in 
acute infarct expansion at the same time that it is 
required for neurorepair during recovery. To 
further study the role of MMP-13 in vascular 
remodeling, MMP-13 mRNA expression was 
transiently silenced in outgrowing populations of 
endothelial progenitor cells (EPCs), confirming 
the role of this collagenase in tubulogenesis 
assays. Our data suggest that MMP-13 is a key 
protease that can be therapeutically modulated 
during both the acute and the recovery phases of 
stroke. 
 
MATERIALS AND METHODS 
Animals 
Age-matched 8- to 15-week-old male MMP-13 
knockout mice (MMP-13 KO in a C57BL/6 
background) and wild-type (WT, C57BL/6) were 
bred in-house in a temperature and humidity 
controlled room and maintained on a 12 hour 
light/dark cycle. The offspring were used for 
these experiments. The founder mice for our WT 
and KO colonies were the kind gifts of Dr. 
Lopez-Otin and were generated as previously 
described (Inada et al., 2004) and crossed into 
congenic C57BL/6 mice for several generations. 
Genotyping analyses were performed to confirm 
that the mice were MMP-13 null, as described 
below. A total of 99 animals (49 WT and 50 
MMP-13 KO) were used in the present study, and 
no mortality was observed during the study 
period. All procedures were approved by the 
Ethics Committee of Animal Experimentation 
(CCEA 67/11) of the Vall d’Hebron Research 
Institute and were conducted in compliance with 
Spanish legislation and in accordance with the 
Directives of the European Union. 
Genotyping analysis 
Freshly obtained mouse tail tissue was used for 
DNA purification 116 to confirm the genotypes of 
randomly selected mice in our colonies. Genomic 
DNA was collected and purified using a Gentra 
Puregene Mouse Tail Kit (Qiagen, Germany) 
according to a protocol provided by the 
manufacturer. Polymerase chain reaction was 
performed using Platinum® Taq DNA polymerase 
(Life Technologies, USA). The following pair of 
Exon primers were used to genotype the 
wild-type mice: (Exon 5F) 
5´TTTATTGTTGCTGCCCATGAG3´ and (Exon 6R) 
5´AGTTTCTCCTCGGAGACTGGT3´. For the 
MMP-13 KO mice, a primer for the neomycin 
resistance gene, (neo) 
5´GACCCACCCCTTCCCAGCCTCT3´, was used as 
the oligonucleotide primer. The approximate 
fragment sizes of each band were 1300 Kb for the 
wild-type and 1485 Kb for the MMP-13 KO on 
agarose gels. 
Focal cerebral ischemia models (MCAo) 
The mice were given free access to food and 
water before surgery. Permanent 
electrocoagulation and transient compression of 
the distal part of the middle cerebral artery (MCA) 
were performed as previously described by our 
group (Morancho et al., 2012). Briefly, the 
animals were anesthetized using 5% isoflurane 
followed by 1.5 - 2% isoflurane for maintenance 
anesthesia via a facemask in medical air (79% 
N2/21% O2; Abbott Laboratories, Madrid, Spain). 
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A small craniotomy was performed in the left 
temporal bone (between the retro-orbital and 
ear area) to expose the MCA. This artery was 
compressed for 60 minutes with a 30-G needle 
using a micromanipulator to perform transient 
MCA occlusion (tMCAo) or electrocauterized for 
permanent MCA occlusion (pMCAo). A heating 
pad connected to a rectal probe was used to 
maintain body temperature between 36.5-37.5°C 
during all surgical procedures. Cerebral blood 
flow (CBF) was monitored using laser-Doppler 
flowmetry (Moor Instruments, UK) to ensure 
appropriate occlusion in both models and 
reperfusion in the tMCAo mice (Morancho et al., 
2012). Only the mice that showed a reduction in 
CBF to below 80% and subsequent reperfusion to 
above 75% of the baseline CBF were included in 
this study. Buprenorphine (0.05-0.1 mg/kg), an 
analgesic, was administered subcutaneously 
immediately after the procedure. The animals in 
the sham group (n=6 for each genotype) were 
subjected to the same procedures (including 60 
minutes of anesthesia for the tMCAo mice), 
except for electrocauterization or compression of 
the MCA. 
A total of 17 mice were subjected to pMCAo (8 
WT and 9 MMP-13 KO), 70 to tMCAo (35 WT and 
35 MMP-13 KO) and 12 to sham surgery (6 WT 
and 6 MMP-13 KO), according to the design of 
the study, as presented in Figure 1. 
 
Figure 1. The study design. Three experimental protocols (A, B and C) were followed to study the role of 
MMP-13 in neuroprotection and neurological repairs after cerebral ischemia. 
 
 
Grip strength neurological test 
The grip strength test is designed to assess the 
peak forelimb force executed by a mouse when 
the mouse releases its front paws from a grid. A 
computerized grip strength meter (Harvard 
Apparatus, USA) was used. The specific protocol 
is described elsewhere (Rosell et al., 2013b). A 
total of 6 trials were conducted for each test, and 
the mean value was calculated as the average 
force used at one time point. This test was 
conducted blindly by a trained researcher before 
the surgery (pre-surgery) and then repeated at 
24 hours, 3days, 7 days and 14 days 
post-ischemia (according to the study groups, A 
and B, as detailed in Figure 1). 
Infarct volume and cortical atrophy 
The mice that were subjected to 60 minutes of 
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occlusion (tMCAo) and the mice in the pMCAo 
group that were included in the infarct volume 
protocol (study A in Figure 1) were transcardially 
perfused with ice-cold saline and euthanized at 
24 hours or 3 days after ischemia. The dissected 
brains were cut into 1 mm-thick coronal sections 
and then stained with 2.5% 
2,3,5-triphenyl-2H-tetrazolium chloride (TTC; 
Sigma-Aldrich, USA) for 15 minutes at room 
temperature. The slices were post-fixed in 
paraformaldehyde (PFA, 4%) and digitalized to 
obtain the measurements. The extension of the 
pale colored ischemic lesion was calculated 
blindly, and the results are presented as the 
percentage of the infarct area (as a % of the 
ipsilateral hemisphere area) or as the corrected 
infarct volume (mm3, corrected for edema), as 
described previously (Morancho et al., 2012). 
Cortical atrophy was evaluated using cresyl violet 
staining at 14 days after tMCAo (as shown in 
study B in Figure 1). Briefly, the mice were deeply 
anesthetized and then euthanized after the brain 
was perfused with ice-cold 4% PFA. The brains 
were harvested and post-fixed in PFA overnight 
at 4°C, followed by cryoprotection in 30% sucrose 
in PBS until the brains sank. Afterward, the brains 
were embedded in optimal cutting temperature 
compound (OCT; Tissue-Tek, Fisher Scientific, 
USA) and stored at -80°C until used. 
Twelve-μm-thick coronal sections including the 
lateral ventricles and the hippocampus were 
collected. Two sections, from bregma +0.02 and 
bregma -1.70, were selected per animal from the 
WT and MMP-13 KO ischemic mice. The sections 
were stained with 0.1% freshly filtered cresyl 
violet containing 0.2% acetate and 0.15% acetic 
acid for 15 minutes at 37°C. The areas of the 
ischemic cortex and the area of the ipsilateral 
hemisphere were measured blindly and the 
results are presented as cortex percentage vs. 
ipsilateral hemisphere. 
Immunohistochemistry (IHC) 
The ischemic animals in protocol B received 
5-Bromo-2’-deoxyuridine (BrdU, 50 mg/kg in 
saline, B9285, Sigma-Aldrich, USA) 
intraperitoneally every 2 days after ischemia. On 
day 7 or day 14, the animals were euthanized, 
and the brain sections were prepared for 
immunohistochemistry as described for the 
atrophy study. Later, the sections were fixed in 
ice-cold acetone and then blocked in 0.1% 
PBS-tween containing 1% BSA and 10% goat 
serum after acid denaturation with 2 M HCl PBS 
for 1 hour. Slides were incubated with the 
following primary antibodies overnight at 4°C 
(DCX) or for 3 hours at room temperature (BrdU 
or NeuN): rabbit anti-doublecortin antibodies 
(DCX, 1:1000, ab18723, Abcam, UK), rat 
anti-BrdU antibodies (BrdU, 1:100, ab6326, 
Abcam, UK) and anti-NeuN antibodies 
conjugated to Alexa Fluor® 488 (NeuN, 1:200, 
MAB377X, Merck Millipore, Germany). Alexa 
Fluor 488 goat anti-rabbit IgG (H+L) and Alexa 
Fluor 647 goat anti-rat IgG (H+L) (1:500, A-1108 
& A-21247, Invitrogen, USA) were the secondary 
antibodies, which were applied, where required, 
at room temperature for 1 hour. The samples 
were then mounted in VectashieldTM with DAPI 
(H-1200, Vector Laboratories, USA) to stain the 
cell nuclei. 
To determine the number of neuroblasts 
migrating from the SVZ to the peri-infarct tissue, 
the DCX+/DAPI+ -labeled area in the SVZ and 
corpus callosum (CC) regions of one slide was 
quantified. In addition, triple-labeled cells 
(DCX+/BrdU+/DAPI+), which indicated the new 
proliferating neuroblasts, were also quantified in 
the SVZ and peri-infarct areas (three selected 
regions of interest (ROIs) in the infarct boundary 
area). The images were obtained at 400X 
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magnification using a confocal laser scanning 
biological microscope (FV1000, Olympus, Japan) 
and analyzed using FV10-ASW software. Finally, 
the mature (NeuN+/DAPI+) neurons in the 
peri-infarct cortical areas adjacent to the 
damaged tissue were imaged at 100X 
magnification and counted using ImageJ software 
(NIH, USA). The results are presented as the 
neurons per area. All analyses were conducted by 
a researcher who was blinded to the genotype 
and group. To study angiogenesis, the mice from 
study B (see Figure 1) were injected 
intravenously (retro-orbitally) with Dylight 
594-labeled tomato lectin (80 μg/mouse, 
DL-1177, Vector Laboratories, USA) 10 minutes 
before euthanized. Two similar isotopically 
oriented slides per animal were selected from 
the brain sections. One image from each section 
that contained the infarct boundary area was 
randomly imaged at 100X magnification. 
Angiogenesis was evaluated as the lectin-positive 
blood vessel density in the selected ROIs and the 
corresponding contralateral areas. The total area 
of the lectin-positive perfused vessels was 
calculated using ImageJ software (NIH, USA) by 
an investigator blinded to the genotype group. 
Multiplex ELISA 
Both the WT and the MMP-13 KO mice (see 
study protocol C in Figure 1) were transcardially 
perfused with ice-cold saline and euthanized at 7 
days after ischemia. The mouse brain tissue 
obtained from both the ipsilateral and 
contralateral cortex was homogenized with 
freshly prepared ice-cold lysis buffer containing 
50 mM Tris-HCl, 150 mM NaCl, 5 mM CaCl2, 0.05% 
BRIJ-35, 0.02% NaN3, 1% Triton X-100, 1% 
phenylmethanesulfonyl fluoride (PMSF; 
Sigma-Aldrich, Switzerland) and 0.5% aprotinin 
(Sigma-Aldrich, USA). Cortical lysates were 
collected from the supernatant after 
centrifugation at 12,000 rpm for 12 minutes at 
4°C. A MILLIPLEX® map mouse 
angiogenesis/growth factor magnetic bead panel 
(MAGPMAG, EMD Millipore, Germany) was used 
to detect angiogenesis-related proteins at day 7 
after ischemia. Briefly, 25 μl of the diluted lysates 
(1:2 in assay buffer) was loaded into the sample 
wells to quantify the levels of angiopoietin-2, 
granulocyte colony stimulating factor (G-CSF), 
amphiregulin, fibroblast growth factor (FGF)-2, 
vascular endothelial growth factor-A (VEGF-A) 
and stromal cell-derived factor- 1α (SDF-1), 
according to the manufacturer’s instructions. The 
assay sensitivity for the different proteins was as 
follows: angiopoietin-2, 5.2 pg/ml; G-CSF, 0.8 
pg/ml; amphiregulin, 2.2 pg/ml; FGF-2, 10.6 
pg/ml; VEGF-A, 0.7 pg/ml and SDF-1, 24.6 pg/ml. 
Each sample was assayed in duplicate, and the 
coefficients of variation were <20%. The results 
are presented as the ratio of the amount of 
protein in the ipsilateral cortex to the amount of 
protein in the contralateral cortex. To evaluate 
the potential MMP protein imbalance in a 
MMP-13 knockdown, a MILLIPLEX® map mouse 
MMP magnetic bead panel 3 (MMMP-3 MAG, 
EMD Millipore, Germany) was run to detect the 
expression of MMP-3, MMP-8 and MMP-9 in 
brain homogenates obtained at 3 days after 
reperfusion (tissues were homogenized right 
after TTC staining), as described above. In brief, 
25 μl of the brain homogenate (1:10 in lysis 
buffer) was loaded into the sample wells. The 
assay sensitivity of the different MMPs was 
MMP-3, 2.5 pg/ml; MMP-8, 3.4 pg/ml and 
MMP-9, 3.1 pg/ml. Each sample was assayed in 
duplicate, and the coefficients of variation were 
<20%. 
EPC cultures and MMP-13 silencing 
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Outgrowth endothelial cells (OECs) with an 
endothelial-like phenotype and a highly 
proliferative nature were obtained from FVB 
wild-type male mice spleens for a previous study 
(Morancho et al., 2013) and stored in liquid 
nitrogen until use. These cells behave as 
competent endothelial cells both in vitro and in 
vivo (Fadini et al., 2012). MMP-13 gene silencing 
was achieved using delivery of passive siRNA via 
Accell SMART pool siRNA (Thermo Scientific, USA) 
according to the manufacturer’s protocol. Briefly, 
2×104 EPCs were seeded in 48-well plates and 
treated separately after 24 h with the respective 
siRNA solutions corresponding to each siRNA 
pool (2 μmol/L). Non-targeting/non-coding siRNA 
was used as a negative control to measure the 
minimal toxicity and side effects of the assay. 
Cyclophilin B (PPIB) siRNA was used as a positive 
control to test the efficiency and specificity of 
MMP-13 silencing. After 48 hours of treatment, 
the cells were thoroughly washed with PBS, 
trypsinized and collected in basal EBM media 
(Lonza, Spain) to perform Matrigel assays, which 
are described below. To confirm the mRNA 
expression in each condition, real-time PCR was 
conducted using the mRNA that was obtained 
from Matrigel-disaggregated cells, which were 
isolated using the Cell Recovery Solution (BD 
Biosciences, USA) for 60 minutes at 4°C. Briefly, 
an RNeasy® Minikit (Qiagen, Germany) was used, 
according to the manufacturer’s instructions, and 
the quantity and quality of the RNA was 
measured using a Nanodrop Spectrophotometer 
and retrotranscribed as cDNA using a High- 
Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, USA). The incubation conditions for 
the retrotranscription were: 10 min at 25°C, 120 
min at 37°C, and 5 min at 85°C. Finally, the 
samples were incubated at 4°C until use or frozen 
at -80°C (Thermal Cycler 2720, Applied 
Biosystems, USA). We included a negative control 
(RNase-free water) for the reverse transcription 
to cDNA to detect possible contamination. 
RT-PCR was performed by mixing 5 μl of Taq Man 
279 Universal 2X PCR Master Mix (Applied 
Biosystems, USA), 0.5 μl of the Taq Man® Gene 
Expression Assay solution (PPIB: Mm 
04208118_gl, GAPDH: Mm99999915_g1, 
MMP-13: Mm00439491_m1; Applied Biosystems, 
USA), 3.5 μl of RNase-free water and 1 μl of the 
sample (cDNA or RNase-free water). These 
experiments were performed in triplicate. A 
sample calibrator was used to compare the 
samples from different reading plates. 
Hybridizations and expression analyses were 
performed using a 7900 thermocycler HT Fast 
Real-Time PCR System (Applied Biosystems, USA), 
and the results were analyzed using SDS 2.3 
software. 
In vitro tubulogenesis 
To assess the angiogenic and/or vasculogenic 
ability of MMP-13 silenced cells, MatrigelTM 
matrix (BD Biosciences, USA) was used for in vitro 
tube formation assays (also named 
tubulogenesis). The experimental groups 
consisted of MMP-13-silenced OECs, 
non-targeting/non-coding siRNA OECs and 
Cyclophilin B (PPIB) siRNA OECs. Briefly, 9,000 
cells were seeded in 96-well plates that were 
previously coated with 50 μl of MatrigelTM matrix 
and then maintained in a CO2 incubator at 37°C. 
After 24 hours, two images per well were 
acquired using an Olympus IX71 microscope 
(100X magnification). Each experiment was run in 
duplicate in four independent experiments. In 
addition, to monitor the formation of vessel-like 
structures by mouse EPCs, a time lapse imaging 
assay was performed over hours, as described in 
a previous study (Morancho et al., 2013). A 
standard MatrigelTM assay was conducted as 
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described above; however, continuous image 
acquisition was performed starting 2 hours after 
seeding and then every 30 minutes (for up to 24 
hours). An Olympus multi-dimensional-TIRFM 
cell-R microscope (Olympus, Japan) with 
temperature, CO2 and humidity control was used. 
Two images per well were acquired at 100X 
magnification. For both assays, the number of 
complete rings, the number of branching points 
and the total tube lengths (the perimeter of 
complete rings) were automatically counted 
blindly using Wimasis® Image Analysis software. 
The results are expressed as a percentage of the 
control condition. 
Statistical Analysis 
SPSS version 15.0 was used for statistical analysis. 
Normality was assessed for continuous variables 
using the Shapiro-Wilk test. The values from the 
normally distributed variables are expressed as 
the mean ± SD and represented as bar graphs. 
The values from the non-normally distributed 
variables are expressed as the median 
(interquartile range) and represented as box 
plots. The differences between the different 
groups were analyzed using an independent 
t-test and ANOVA and, if significant, followed by 
the Dunnett post hoc test (all vs. the control 
condition) if normally distributed or the 
Mann-Whitney U-test and Kruskal-Wallis if not 
normally distributed. To assess differences 
between time-points, we used repeated ANOVA 
followed by Bonferroni post hoc tests. Finally 
differences between categorical variables were 
analyzed using Fisher’s exact tests or Chi Square 
tests. A p-value less than 0.05 was considered 
statistically significant. 
RESULTS 
MMP-13 deficiency protects the brain from 
ischemia-reperfusion injury and improves 
functional outcomes 
The WT and KO alleles for MMP-13 were 
confirmed using PCR (Figure 2A). The brain 
infarct was localized to the somatosensory and 
motor cortex in both the permanent and the 
transient model (Morancho et al., 2012). 
Unexpectedly, 4 WT mice presented some infarct 
expansion that affected the striatum at 3 days 
after MCAo. MMP-13 deficiency reduced infarct 
volume in the ischemia-reperfusion model at 
both 24 hours and 3 days (26.1±9.4 mm3 for WT 
vs. 14.4±8.3 mm3 for MMP-13 KO, p=0.025; and 
24.8±4.7 mm3 for WT vs. 9.3±3.1 mm3 for 
MMP-13 KO, p<0.001; respectively), as shown in 
Figure 2B-C. However, this difference was not 
significant in the permanent occlusion model 
(19.1±8.7 mm3 for WT vs. 14.5±6.5 mm3 for 
MMP-13 KO, p=0.228). The difference between 
these two ischemia models was attributed to the 
increase in infarct extension observed in the WT 
mice subjected to tMCAo, although this 
difference did not reach statistical significance at 
24 hours (19.1±8.7 mm3 for pMCAo vs. 26.1±9.4 
mm3 for tMCAo, p=0.13) or at 3 days (19.1±8.7 
mm3 for pMCAo vs. 24.8±4.7 mm3 for tMCAo, 
p=0.105). An analysis of functional outcomes also 
confirmed a significant decrease in forelimb force 
at 24 hours in the WT mice (decreased 83.8±15.8% 
from baseline, p<0.01); however, this was not 
clearly observed in the MMP-13 KO mice despite 
a statistical trend (90.2±23.9% from baseline, 
p=0.083); see Figure 2D. No differences were 
observed between mice with different genotypes 
at either 24 hours or 3 days (data not shown). 
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Figure 2. MMP-13 deficiency protects brain tissue during cerebral ischemia reperfusion.   Genotype 
characterization of wild-type (WT) and MMP-13 knockout (KO) mice: a 1300Kb band indicates a WT allele, and 
a 1485Kb band indicates a MMP-13 KO allele (A). TTC staining showing infarct areas at 24 h and 3 days after 
60 min of transient ischemia (B). Bar graph showing mean ± SD infarct volume at 24 h and 3 days; 
n=6-8/group, * P<0.05 and ** P<0.01 (C). Grip strength measurements confirming that the significant 
neurological impairment observed in WT mice was reduced in MMP-13-deficient animals; n=13-14/group, ** 
P<0.01 vs. pre-tMCAo (D). 
 
 
Interestingly, we observed more spontaneous 
intracranial hemorrhagic transformations at 3 
days than at 24 hours, and this was more 
common in the WT (6/6 and 4/8, respectively) 
than in the MMP-13 KO mice (3/6 and 1/7, 
respectively), as shown in representative images 
of the WT in Figure 2B. The differences between 
genotypes or reperfusion day were not 
statistically significant, however if the only 
presence of HT was considered, regardless the 
duration of MCAo, MMP-13 deficiency protected 
brains from spontaneous hemorrhagic 
conversions (10/14 in WT vs. 4/13 in MMP-13-KO, 
p=0.035, supporting Table 1 and Figure 1). The 
animals studied over a longer time (two weeks, 
study B) showed significant differences in 
forelimb force between WT and MMP-13 KO at 
24 hours and 1 week after tMCAo (p=0.035 and 
p=0.015, respectively). When the neurological 
outcomes within the groups were analyzed, only 
the WT mice exhibited a significant decrease in 
forelimb force values vs. baseline at 1 week 
(66±4.6%, p<0.001) and 2 weeks (70.2±5.7%, 
p=0.017), as shown in Figure 3A. At two weeks, 
differences in forelimb force were no longer 
observed. 
MMP-13 and cortical damage 
Cerebral ischemia leads to brain damage at the 
same time that it triggers neurorepair 
mechanisms. Cortical atrophy was evaluated at 
14 days after tMCAo as a percentage of the 
remaining cortex in the ipsilateral hemisphere 
(35.7±1.9% for WT vs. 36.1±1.7% for MMP-13 KO, 
p=0.684) as shown in Figure 3B, regardless of 
large differences in baseline infarct volumes. 
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Figure 3. Recovery from brain ischemia reperfusion. Grip strength performance: MMP-13 KO mice were 
acutely protected from functional impairment following cerebral ischemia. After two weeks, differences 
between genotypes were no longer observed. n=8, *P < 0.05, **P < 0.01 vs. pre-tMCAo in the same cohort; 
#
P 
< 0.05 vs. WT at the same time point (A). Cortical atrophy of the ipsilateral hemisphere at 2 weeks, n=8 (B). 
 
 
A reduced number of newly born neuroblasts 
was observed in the peri-infarct areas of the 
MMP-13 deficient mice during recovery 
DCX+ neuroblasts/immature neurons and 
proliferating cells were studied in the post stroke 
brain during recovery (at days 7 and 14), with a 
focus on the SVZ, the corpus callosum (CC) and 
peri-infarct areas. At the studied time-points, no 
enhanced neuroblast migration was detected at 
day 7 compared with the contralateral side in 
either the WT or the MMP-13 KO mice (Figure 
4A), whereas at day 14, the number of 
neuroblasts was higher in the ipsilateral CC area 
than in the contralateral CC in both the WT and 
MMP- 13 KO mice (p=0.011 and p=0.011, 
respectively; see Figure 4B). Interestingly, when 
we analyzed the distribution of the BrdU+ 
replicating cells in the post-stroke brain (day 14), 
we found a reduced number of newly born 
neuroblasts (DCX+/BrdU+) in the peri-infarct 
areas of the MMP-13 deficient mice (18.0±2.8 
cells in WT vs. 4.7±1.3 cells in MMP-13 KO, 
p=0.001), although a similar number of DCX+ 
cells was found in the same area (136±27 cells in 
WT and 130±20 cells in MMP-13 KO, p=0.873; 
see Figure 4C-D). An additional analysis of these 
cell counts also showed that the percentage of 
newly born neuroblasts (DCX+/BrdU+) out of the 
total number of neuroblasts was reduced in the 
peri-infarct areas of the MMP-13 deficient mice 
(16.9% in WT vs. 4.8% in MMP-13 KO, p=0.005). 
Immunostaining for mature neurons (NeuN+) did 
not reveal any difference between mice with 
different genotypes in numbers or size (data not 
shown). 
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Figure 4. Neuroblast migration from the SVZ through the CC to the peri-infarct cortex. DCX+ (neuroblast) 
area quantification in the dorsolateral ventricle (DL) area and the corpus callosum (CC) area, as indicated, at 
day 7 (A, n=5-6) or day 14 after tMCAo (B, n=8); **P <0.01. The micrographs confirm peri-infarct neurogenesis 
(the areas studied in selected ROIs) as co-staining between DCX (green), BrdU (yellow), lectin (red) and DAPI 
(blue, nuclei) on day 14 after tMCAo (C), the white arrows indicate a newborn neuroblast. The bar graphs 
show that MMP-13 deficiency decreased the number of DCX+/BrdU+-stained proliferating neuroblasts in the 
peri-infarct cortex; n=8, **P<0.01 (D). 
 
 
MMP-13 is a key protease during post-stroke 
vascular remodeling 
Accelerated angiogenesis in the peri-infarct area 
is closely related to improved post stroke tissue 
repair (Hayashi et al., 2006). In the present study, 
we sought to study the functional brain 
microvasculature using in vivo endothelial 
labeling with lectin, as described. Our data show 
that 7 days after cerebral ischemia, no difference 
in peri-infarct vessel density (the percentage of 
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the lectin-stained area of the ROIs, as shown in 
Figure 5A) occurred as a consequence of 
ischemic insult in either the WT (3.11±0.35 in the 
ipsilateral vs. 3.15±0.47 in the contralateral side, 
p=0.861) or the MMP-13 KO mice (3.16±0.64 in 
the ipsilateral vs. 3.37±0.60 in the contralateral 
side, p=0.578). Nevertheless, on day 14, the WT 
mice presented higher vessel density in the 
peri-infarct cortex than in the corresponding 
contralateral area (3.03±0.41 vs. 2.45±0.19, 
p=0.003; Figure 5B-C), whereas the MMP-13 KO 
mice did not display ischemia-enhanced 
angiogenesis in the peri-infarct area (2.53±0.51 
vs. 2.24±0.20, p=0.160; Figure 5B-C). Accordingly, 
the WT mice presented a more extensive vessel 
area than the MMP-13 KO mice in the peri-infarct 
cortex (3.03±0.41 vs. 2.53±0.51, p=0.049), and 
this was also observed, although less extensively, 
in the contralateral cortex, where it did not reach 
statistical significance (2.45±0.19% in WT vs. 
2.24±0.20% in MMP-13 KO; p=0.05; Figure 5B-C). 
No differences were observed in the peri-infarct 
area in the striatum, as expected, in the distal 
cortical experimental model of stroke (data not 
shown). Interestingly, we studied whether the 
number of proliferating neuroblasts (DCX+/BrdU+ 
cells) was related to vessel density and observed 
a noticeable association between these studied 
parameters, as shown in the correlation plot in 
Figure 5D (p=0.056). 
 
Figure 5. Brain vessel density after ischemia reperfusion. Representation of the studied areas (indicated by 
squares), (A). Micrographs of Lectin+ (red) vessels in representative brains; scale bar represents 200 μm (B). 
Bar graphs representing vessel density in the peri-infarct cortex and the corresponding contralateral area on 
days 7 and 14 after tMCAo; n=6-8, **P<0.01 and *P<0.05 (C). Correlation plot between vessel density and the 
number of proliferating neuroblasts in peri-infarct areas on day 14 (D). 
 
 
In agreement with this temporal profile, the 
levels of several angiogenesis-related growth 
factors were examined in the ischemic brain at 
day 7, which is just before the increase in vessel 
density observed in the peri-infarct tissue. Data 
obtained from immunodetection assays showed 
that G-CSF (shown as a ratio of 
ipsilateral/contralateral) was higher after 
ischemia in the WT mice than in the sham group 
(5.1 (1.9-10.5) vs. 1.1 (0.8-1.8), respectively; 
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p=0.003). At the same time-point, the 
MMP-13-deficient ischemic mice presented a 
lower level of cortical G-CSF than the 
corresponding WT mice (2.5±1.5 vs. 5.2±2.7, 
p=0.031; see Figure 6A). In agreement with these 
results, the expression of other growth factors 
associated with vascular remodeling was also 
significantly lower in the infarct cortex of 
MMP-13 KO mice than in the WT mice, for 
example, VEGF-A (0.9±0.3 vs.1.4±0.3, p=0.007) 
and amphiregulin (0.9±0.2 vs. 1.1±0.2, p=0.049; 
see Figure 6A). Other growth factors, such as 
angiopoietin-2, FGF-2 and SDF-1 were also 
down-regulated in the MMP-13 KO brains but 
these differences were not significant when 
compared to the WT (not shown). To explore 
effects on other members of the MMP family of 
proteins that might potential compensate for 
MMP-13 knockdown, the levels of three MMPs 
(including another collagenase, MMP-8) were 
quantified in the ischemic cortex and the 
corresponding contralateral tissue. Interestingly, 
our results show that the levels of MMP-3, 
MMP-8 and MMP-9 were significantly elevated in 
the damaged cortex in mice with both genotypes 
compared to the contralateral cortex, as shown 
in Figure 6B. Moreover, the amount of these 
MMPs was considerable higher in the ipsilateral 
cortex of WT mice than in the MMP-13 KO mice: 
1.21 (0.55-1.78) ng/mg vs. 0.14 (0.09-0.20) 
ng/mg for MMP-3, p=0.002; 0.8±0.2 ng/mg vs. 
0.4±0.1 ng/mg for MMP-8, p=0.001; and 2.4±0.9 
ng/mg vs. 0.7±0.3 ng/mg for MMP-9, p=0.002. 
These results support the idea that MMP-13 
plays a role as a central protease that regulates 
other MMPs after ischemia. 
 
Figure 6. Pro-angiogenic factors and MMPs in the cortex after ischemia. Bar graphs representing the ratio of 
MMP proteins between the ipsilateral (IP) and contralateral (CL) hemispheres in WT and MMP-13 KO ischemic 
mice at 7 days after ischemia; n=7-8, *P<0.05, **P<0.01 (A). Box plots and bar graphs demonstrating the 
overexpression of other MMPs in the ipsilateral hemisphere of WT brains and their dysregulation in 
MMP-13-deficient mice at day 3. **p<0.01 and 
## 
p<0.01 vs. ipsilateral (B). Data are expressed as ng of MMP 
per mg of total protein. 
 
Transient silencing of the MMP-13 gene impairs 
tubulogenesis in vitro 
To determine whether the 
angiogenic/vasculogenic functions of OECs are 
controlled by MMP-13, an in vitro MatrigelTM 
assay was conducted after MMP-13 expression 
was silenced using siRNA. As shown in Figure 7A, 
 54 
  
introducing MMP-13 siRNA into OEC cell cultures 
reduced the expression of MMP-13 mRNA by 
68.62% compared with the control cells 
(p=0.001). This effect occurred without 
modifying the expression of housekeeping genes, 
such as PPIB. Additional experiments were 
conducted to demonstrate that the precise 
targeting of other genes, such as PPIB, 
successfully reduced their expression (up to 
93.63, p<0.001) without modifying MMP-13 
expression, as shown in Figure 7A. Nonspecific 
(non-targeting) siRNA did not modify any of the 
expression patterns of MMP-13 or PPIB.  
 
 
Figure 7. Tubulogenesis network formation in Matrigel
TM
 assays of mouse OECs after silencing MMP-13 
expression. Bar graphs represent the level of MMP-13 and PPIB RNA expressed in each culture condition; n=4, 
**P<0.01 vs. Control (A). Representative micrographs showing vessel-like structures shaped by OECs in 
different treatment groups (B). The bar graphs show the quantification of the number of branches, the total 
tube lengths and the loops of vessel-like structures that were induced in non-silenced, MMP-13-silenced and 
PPIB-silenced OECs; n=4, *P<0.05 vs. non-targeting siRNA EPCs (C). 
 
MatrigelTM functional assays showed that OECs 
that did not endogenously express MMP-13 
formed aberrant tubulogenic networks compared 
with all the other tested conditions (see Figure 
7B and supporting Videos 1-4). The total number 
of branching points and loops and the total tube 
lengths of the vessel-like structures were 
quantified. Compared with the non-targeting 
siRNA (control group), the MMP-13-silenced 
OECs showed decreased numbers of vessel-like 
structures, as assessed by the analysis of all 
parameters. The difference in the percentage of 
loops (circular structures) reached statistical 
significance (p=0.019), whereas the percentage 
of branches and the percentage of tube lengths 
are presented as statistical trends after the 
statistical analyses among the groups (p=0.132 
and p=0.052, respectively), as shown in Figure 
7C.  
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DISCUSSION 
The present study demonstrates for the first time 
that collagenase-3 (MMP-13) participates in 
tissue damage during cerebral ischemia and is 
simultaneously required for neurovascular 
remodeling during the recovery phases. MMP-13 
deficiency reduced infarct size and acutely 
diminished the deterioration of functional 
outcomes observed after experimental transient 
cerebral ischemia. However, the absence of 
MMP-13 also reduced the amount of newly born 
neuroblasts in the peri-infarct areas during 
neurological recovery and altered stroke-induced 
angiogenesis by reducing peri-infarct 
angiogenesis and suppressing the secretion of 
G-CSF, angiopoietin-2 and VEGF-A. Finally, 
endothelial progenitor cell function 
(demonstrated in their high potential for vascular 
remodeling) was abolished when MMP-13 gene 
expression was silenced in vitro. 
Stroke leads to cell and tissue death within 
minutes/hours because the brain spontaneously 
activates both injury and repair mechanisms that 
compete for the recruitment of tissue after an 
ischemic insult (Lo EH, 2008). This state opens a 
new battlefield wherein neuroprotection is 
needed to minimize the expansion of the injury 
and neurorepair strategies are needed to 
enhance endogenous repair. Among the known 
neurorepair mechanisms is the process by which 
cerebral ischemia triggers spontaneous 
neurogenesis (Ohab et al., 2006; Kreuzberg et al., 
2010), angiogenesis (Ergul et al., 2012) and 
gliogenesis (Tanaka et al., 2003; Miyamoto et al., 
2010) in peri-infarct areas. From a mechanistic 
point of view, our efforts have been focused on 
MMPs, which are zinc-dependent 
endopeptidases that degrade components of the 
extracellular matrix, including the basal lamina 
surrounding brain microvessels, which are 
modified during angio-vasculogenesis. Some 
MMPs have been found to contribute to brain 
injury (Asahi et al., 2001; Gidday et al., 2005) and 
also to orchestrate vascular remodeling 
(Morancho et al., 2013; Zhao et al., 2006). 
Knowledge regarding the role of MMP-13 is 
limited in the context of stroke.  
In our study, both MMP-13 KO and WT mice were 
subjected to permanent or transient ischemia; 
however, the infarct size was only significantly 
reduced in the MMP-13- deficient mice in the 
transient model at both 24 hours and 3 days after 
MCAo, indicating that the role of MMP-13 in 
tissue damage is most likely more related to the 
reperfusion phase. The infarct volume did not 
change in the MMP-13-KO mice; however, more 
damage was observed in the WT mice in the 
transient model than in the permanent model. In 
addition, we unexpectedly observed 
spontaneous hemorrhagic transformations in our 
model (especially at day 3), but the knockdown 
of MMP-13 partially protected mice from 
suffering these complications. Previous results 
from our laboratory revealed a relationship 
between a high plasma level of MMP-13 and 
early brain lesion growth in stroke patients 
(Rosell et al., 2005). We identified an increase in 
MMP-13 protein levels in the infarct/peri-infarct 
areas in human and rat tissues, and the 
activation of neuronal nuclei has been related to 
cell death in oxygen- and glucose deprivation 
studies (Cuadrado et al., 2009a and 2009b). 
Recently, increased MMP-13 mRNA and protein 
levels were observed in brain tissue during the 
acute phase of ischemia reperfusion by Lenglet 
and colleagues (Lenglet et al., 2014). Other 
authors have reported that injured endothelial 
cells release MMPs, including MMP-13, which 
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attack the basal lamina and degrade the matrix 
components and tight junctions of endothelial 
cells (Hattori et al., 2003). Ueno and colleagues 
found that the expression of MMP-13 in 
hippocampal vessels was increased in rats with 
blood brain barrier (BBB)- damaged vessels 
compared with rats without BBB impairment, 
indicating the importance of MMP-13 
recruitment to brain tissue during the healing 
process, where it participates in angiogenesis 
and neurogenesis (Ueno et al., 2009). Indeed, it 
has been demonstrated that a high level of 
MMP-13 activity lasts for up to 14 days after 
ischemia, and this appears to be closely 
associated with an increase in aggrecan, 
suggesting their role in neuronal reorganization 
(Nagel et al., 2005). All these data support a role 
for MMP-13 in the acute and subacute phases of 
stroke: MMP-13 participates in the development 
of acute ischemic damage, while at the same 
time contributing to favorable neurovascular 
remodeling during recovery. As we will discuss in 
detail, the results in this report support these 
hypotheses.  
The distal MCAo model was chosen for this study 
due to its association with low mortality rates 
and for the precise infarct location it induces in 
cortical areas, which leads to a defined cortical 
peri-infarct area. However, cortical damage tends 
to produce milder neurological deficits over the 
long-term. In our experience, the grip strength 
test has been proven to be a feasible method for 
short- and long-term evaluations after distal 
MCAo (Rosell et al., 2013b). Our data show that 
the WT mice presented increased neurological 
deterioration in the first week. No difference was 
detected in the MMP-13 KO mice, supporting a 
protective role for MMP-13 in acutely induced 
neurological deficits. Moreover, significantly 
different effects on neurological functions were 
observed between the genotypes during the first 
week after ischemia (the WT mice performed 
worse); however, this difference disappeared at 2 
weeks, at which time the WT mice showed 
improved results in the forelimb force test. These 
data support the idea that MMP-13 is implicated 
in the post-stroke spontaneous-recovery phase at 
a functional level. In this regard, our results also 
showed that similar cortical atrophy occurred in 
MMP-13 KO and WT mice at 2 weeks, despite the 
larger infarct volumes observed in WT mice, 
which could be a consequence of different 
capabilities related to neurorepair, the inhibition 
of cell apoptosis or the promotion of neuronal 
survival, among other mechanisms. It will be 
interesting to perform studies using longer time 
points to follow-up on these observations 
regarding the state of atrophy in the damaged 
tissue.  
Neurogenesis and angiogenesis were studied to 
further explore the mechanisms affected by the 
lack of MMP-13 that could influence cerebral 
plasticity. Our results confirm that at 2 weeks, 
neuroblasts had migrated to the peri-infarct 
areas, as has been described to occur in 
post-stroke brains (Arvidsson et al., 2002; 
Carmichael, 2008). This effect occurred from the 
SVZ through the corpus callosum, as expected, 
and no difference was observed between the 
genotypes. Interestingly, the peri-infarct areas of 
the mice lacking MMP-13 contained a reduced 
number of proliferating neuroblasts 
(DCX+/BrdU+), which are responsible for the 
formation of new neural cells in the areas 
showing active neurorepair. Most neuroblasts die 
during migration and the generation of new 
neurons (Zhang et al., 2004). We hypothesized 
that either the microenvironment in peri-infarct 
areas and along the migration pathways in brains 
lacking MMP-13 did not support neuroblast 
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survival or that lack of MMP-13 may result in 
decelerated standard migration patterns. In this 
regard, neurogenesis has been shown to be 
coupled to angiogenesis in a post-stroke 
neurovascular niche (Ohab et al., 2006), and it 
has been demonstrated that blood vessels in the 
peri-infarct cortex secrete soluble factors that 
maintain neurogenic potential and guide 
neurogenesis toward the damaged cerebral 
cortex (Shen et al., 2004; Thored et al., 2007). In 
support of these hypotheses, we observed a 
positive association between the number of 
proliferating neuroblasts and lectin-positive 
vessels in tissues with more extensive vessel 
networks and the ones that presented more 
newborn neuroblasts in the peri-infarct area.  
Importantly, our study shows that at day 7 after 
ischemia-reperfusion injury, lower amounts of 
some nourishing factors, such as G-CSF, 
angiopoietin-2 and VEGF-A, were observed in the 
infarct cortex of the MMP-13 KO mice than in the 
WT brains. This is an interesting finding because 
the administration of some factors in the early 
stages of stroke has been shown to stimulate 
angio-neurogenesis and to lead to improved 
functional recovery (Schäbitz et al., 2003; Rivera 
and Bergers, 2014; Beck et al., 2000). These data 
suggest that MMP-13 could be indirectly 
contributing to an appropriate angiogenic 
micro-environment. Therefore, we expected to 
observe changes in vessel density between the 
MMP-13 and WT mice. In agreement with this 
assumption, our observations support a role for 
MMP-13 in vascular remodeling after stroke: two 
weeks after cerebral ischemia, increased vessel 
density in the peri-infarct area was found only in 
the WT animals and not in the MMP-13-deficient 
mice. The present study does not identify the 
source of the trophic factors that are affected by 
MMP-13 deficiency. These could be secreted by 
brain resident cells, such as astrocytes or mature 
endothelial cells, as has been described by others 
(Ohab and Carmichael, 2008; Kahle and Bix, 
2013). However, they could also be released by 
stem/progenitor cells, such as EPCs or NPCs, 
which secrete multiple growth factors (Rosell et 
al., 2013a; Drago et al., 2013; Urbich et al., 2011). 
EPCs have been demonstrated to have 
therapeutic potential in that they 626 directly 
enhance angiogenesis and neurogenesis 
(Asahara et al., 1997; Carmeliet, 2003; Ma et al., 
2015). These cells, which are also the source of 
multiple trophic factors, are able to differentiate 
into cells with an endothelial phenotype and 
have been proven to reduce the brain damage 
caused by ischemia and to enhance 
angio-vasculogenesis in stroke models (Ohta et 
al., 2006; Moubarik et al., 2011; Rosell et al., 
2013a). In the present study, we further 
demonstrated a role for MMP-13 in tubulogenic 
remodeling in experiments in which we silenced 
the expression of MMP-13 in EPCs, which have 
been shown to be involved in angiognesis 
(Morancho et al., 2013; Rosell et al., 2013a). Our 
data demonstrate that EPCs develop abnormal 
tubulogenic remodeling patterns when MMP-13 
expression is blocked, in which they failed to 
shape vessel-like networks in MatrigelTM 
substrate. This interesting observation should be 
considered for future therapeutic strategies, 
although additional research in an in vivo setting 
is needed to study the effects of MMP-13 
deficiency in tissue EPCs or in putative EPC-based 
cell therapies. 
In summary, our study highlights the role of 
MMP-13, a pivotal collagenase that remodels the 
ECM, in neuroprotection and neurorepair after 
cerebral ischemia. This central role is further 
supported by our findings regarding the 
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regulation of other MMPs in the ischemic brain. 
We demonstrate that in WT mice, other MMPs, 
including MMP-3, MMP-8 and MMP-9, are 
upregulated in the ischemic brain, as was 
reported by our group in human infarct tissue 
(Cuadrado et al., 2009b), but also that MMP-13 
deficiency considerably diminished the 
overexpression of these other MMP family 
members. 
Therefore, lacking MMP-13 protects the brain 
and improves functional outcomes over the short 
term, whereas over longer periods of time, this 
protease is required to support vascular 
remodeling and the production of growth factors 
that are linked to peri-infarct neurogenesis. In 
conclusion, the therapeutic modulation of 
MMP-13 during stroke is fully supported by the 
present data. 
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SUPPORTING INFORMATION 
 
Supporting Table 1. 
 
Supporting Table 1. Summary of HT incidences in MMP-13 KO and WT mice after transient MCAo.  
 
HT incidence 24 hours post-ischemic 
reperfusion 
72 hours post-ischemic 
reperfusion 
P value 
WT (10/14)  50% (4/8) 100% (6/6) 0.085 
MMP-13 KO (4/13)  14.3% (1/7) 50% (3/6) 0.266 
0.035 0.282 0.182 
 
 
 
 
 
 
 
 
Supporting Figure 1. 
 
 
Supporting Figure 1. Representative images of HT at 24h or 72h after cerebral ischemia in WT or 
MMP-13 KO mice. 
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Supporting video 1. 24 hours of time-lapse imaging Matrigel
TM
 assay of mouse WT control OECs 
(100X) 
http://ees.elsevier.com/ynbdi/download.aspx?id=341324&guid=a0d8c941-d09c-4535-b9dc-4c39268a
43ca&scheme=1 
 
Supporting video 2. 24 hours of time-lapse imaging Matrigel
TM
 assay of mouse WT MMP-13 silenced 
OECs (100X) 
http://ees.elsevier.com/ynbdi/download.aspx?id=341325&guid=03bb1fa4-322e-4b11-9d35-6bd4a99d
f1e8&scheme=1 
 
 
Supporting video 3. 24 hours of time-lapse imaging Matrigel
TM
 assay of mouse WT PPIB silenced OECs 
(100X) 
http://ees.elsevier.com/ynbdi/download.aspx?id=341326&guid=12a5e1be-4f0d-4de9-9547-f115b74c
6ad7&scheme=1 
 
 
Supporting video 4. 24 hours of time-lapse imaging Matrigel
TM
 assay of mouse WT No-targeting 
silenced OECs (100X) 
http://ees.elsevier.com/ynbdi/download.aspx?id=341327&guid=0d57cc95-fd0d-4708-94de-058d8253
d2da&scheme=1 
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ABSTRACT 
Background: Rehabilitation therapies are still the 
only approved treatments used to improve 
neurological recovery in disabled stroke survivors. 
The use of biomarkers to monitor and predict 
patient’s recovery could help to adjust individual 
rehabilitation programs and to identify 
mechanisms of repair. Objective: To study plasma 
levels of matrix metalloproteinases (MMPs) as 
potential markers of recovery during intensive 
rehabilitation therapy (IRT) after stroke. Methods: 
Patients with first-ever ischemic strokes enrolled 
to IRT (≥3 hours per day/5 days per week) were 
studied (n=15). The protocol consisted of a 
battery of motor/functional tests (Rankin, BI, 
FMA, FAC, MRC, CAHAI and the 10 meter walk) 
performed before therapy and at one-, three and 
six-month follow-ups, in addition to blood 
extractions to measure MMP-3, MMP-12 and 
MMP-13 levels. Healthy volunteers served as 
non-ischemic controls (n=15). Results: MMP 
levels remained stable during the study period 
and were similar to those in controls. However, 
baseline MMP-12 and MMP-13 levels were 
strongly associated with stroke severity as 
measured by NIHSS score (p<0.001 and p=0.008) 
and were elevated in the patients with the most 
extensive infarcts (p=0.009 and p=0.058). 
Interestingly, plasma MMP-3 was independent of 
baseline stroke characteristics but was found to 
be increased in patients with better 
motor/functional recovery and in patients with 
larger improvements during rehabilitation. 
Conclusions: MMPS might act as biological 
markers of recovery during rehabilitation therapy 
related to their roles in both injury and tissue 
remodeling. Future confirmatory investigations in 
multicenter studies are warranted by our data. 
 
Key Words: Stroke, matrix metalloproteinase, 
intensive rehabilitation therapy, biomarker, 
recovery   
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INTRODUCTION  
Despite enormous advances in acute stroke 
management during the last two decades (1), 
approximately five million people survive a stroke 
each year worldwide with disabilities that limit 
independence for several types of daily activities. 
For these patients, the only approved treatment 
during the sub-acute and chronic phases of the 
disease is neurorehabilitation, with the objective 
of improving their independency status and to 
reach the best quality of life at long-term (2, 3).  
During rehabilitation, improved outcomes in 
patients are the result of early mobilization, 
rehabilitation intensity and other measures used 
to prevent and treat medical complications (4, 5), 
and also to individual responses to therapy. From 
a biological perspective, we know that 
neurorehabilitation enhances different aspects of 
brain plasticity, such as axonal remodeling, cell 
genesis and angiogenesis (6), but this could be 
patient-dependent, and the biological 
mechanisms responsible for these individual 
responses to treatment are still being 
investigated. With this background, it is 
necessary to investigate the precise molecular 
mechanisms underlying tissue remodeling and 
plasticity to ameliorate or adjust current 
rehabilitation programs. Additionally, the 
accessibility of biomarkers that could support an 
accurate and individual prognosis of recovery 
during rehabilitation would help practitioners to 
decide on the intensity, type or duration of the 
program and to personalize treatments (7).  
In this investigation, we have focused on matrix 
metalloproteinases (MMPs), enzymes that can 
degrade most components of the extracellular 
matrix that are involved in both injury and tissue 
repair after stroke (8, 9). We have investigated 
MMP-3, MMP-12 and MMP-13 as they were 
previously related to ischemic brain injury but 
not to recovery after stroke. Our hypothesis is 
that some of these MMPs can serve as 
biomarkers to monitor individual neurological 
status and/or functional improvement as a 
reflection of the brain plasticity phenomena and 
an individual response to rehabilitation therapy.  
We designed a prospective study of ischemic 
stroke patients who were enrolled in intensive 
rehabilitation therapy (IRT) to measure plasma 
levels of MMPs and to determine the 
motor/functional status of the patients by using 
a battery of tests up to six months after stroke.  
 
METHODS 
Study Subjects 
The study cohort comprised patients who were 
enrolled in IRT at the Vall d’Hebron University 
Hospital from February 2014 to February 2015. 
Inclusion criteria were: first-ever ischemic stroke, 
age < 70 years, somatosensory or ataxic 
hemiparesis, time until start of IRT < 3 weeks 
after stroke, stable medical condition, endurance 
to participate in a minimum of 3 hours/day in a 
therapy program and agreement to participate in 
the study. Exclusion criteria included sensory or 
global aphasias, cognitive deficits (Mini-Mental 
State Examination < 23), terminal illness, 
inflammatory diseases or previous deficits of the 
upper/lower limb. In parallel, fifteen 
non-ischemic healthy individuals with no known 
neurological, malignant or inflammatory disease 
volunteered to participate as part of the control 
cohort. Part of the control cohort were 
hypertensive subjects also studied in the YSSIS 
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study (10) free of ischemic events.  
The Study Protocol was presented and approved 
by the local Clinical Research Ethics Committee 
(PRIR 317/2013). All patients and controls signed 
the corresponding informed consent.  
Rehabilitation Intervention 
Patients who met the inclusion criteria followed a 
comprehensive intensive rehabilitation program, 
including physiotherapy, occupational therapy, 
speech therapy and/or neuropsychology, if 
required, for a minimum of 3 hours per day and 5 
days per week, as indicated by the Catalan 
clinical practice guidelines for the management 
of stroke (11). The protocol started with a 
physiatrist assessing patient’s deficits within the 
first 24 hours after stroke and designing an initial 
rehabilitation program. Passive mobilizations 
performed in bed started within the first 24 
hours after stroke if there are no medical 
conditions that contraindicate it, and at 48 hours 
patients started a moderate intensity 
rehabilitation program. Those patients who 
presented severe or moderate deficits in two or 
more functional areas and who met the inclusion 
criteria for an intensive rehabilitation program 
were transferred to the Neurorehabilitation Unit 
for inpatient IRT, whereas those patients who 
were able to walk with some support/assistance 
were released to their household and started the 
daily IRT at the Day hospital of the 
Neuro-Rehabilitation Unit. With the posterior 
release from the inpatient Neurorehabilitation 
Unit, the IRT then continued at the Day Hospital 
until completion of a minimum of 75% of the 
proposed objectives or when functional stability 
was achieved. If there were further objectives, 
the patient continued a high-moderate intensity 
outpatient rehabilitation program until the 
achievement of functional stability. 
Study Protocol 
A total of fifteen patients were finally included in 
the study. Of these, one patient was excluded 
following the baseline visit after having a second 
stroke, while another patient voluntarily 
discontinued his participation. Two other 
patients chose to withdraw from the study after 
the one-month follow-up visit (see Figure 1). 
 
 
Figure 1. Study flow diagram. 
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Data related to subject demographics, risk factors, 
medication, comorbidities and exercise were 
obtained from patients and controls (see Table 1), 
along with clinical stroke characteristics (see 
Table 2).  
Specific visits for the study were performed by an 
experienced physiatrist at baseline prior to 
starting the IRT and at one, three and six months 
after starting the therapy program (see Figure 1). 
During these visits, several tests and scales were 
performed to assess motor function and 
functional status (see details below), and blood 
was extracted in EDTA tubes and centrifuged at 
1500 rpm for 15 minutes to obtain plasma, which 
was stored at −80 °C until use. 
Functional/Motor Measures Assessment and 
Definition of improvement 
The battery of tests consisted of the modified 
Rankin scale (mRS, 0-6), the Granger's modified 
BI (12) (BI, 0-100), the Fugl-Meyer Assessment 
score for the upper extremity (FMA, 0-66), the 
Functional Ambulation Categories (FAC, 0-5), the 
Chedoke Arm and Hand Activity Inventory (CAHAI, 
13-91) (13), the 10-meter walk test and the 
Medical Research Council (MRC) (scale 0-5) of 
the disabled hemisphere (upper and lower 
extremities at the proximal/distal level).  
Improvement classifications were obtained after 
comparing the scores during follow-up visits 
versus baseline scores: in FMA was defined as an 
increase ≥ 10 points, described previously as the 
minimal clinical important difference (14). For 
the CAHAI, an improvement was defined as an 
increase of ≥ 7 points (15). For the 10-meter 
Walk Test, the walking velocity was calculated 
and improvement was considered if walking 
velocity increased by more than 0.3 m/sec (16). 
The FAC was categorized into three categories: 
“cannot walk” (score 0), “dependent walk” (score 
1-3) and “independent walk” (score 4-5), and 
improvement was defined as a shift to an upper 
category (17). For MRC, our analysis 
differentiated between normal (score 5) or 
impaired (score 0 to 4) muscle strength. 
Plasma MMP measure 
Plasma levels of soluble MMP-3, MMP-12 and 
MMP-13 were measured with the MILLIPLEXR 
map Human MMP Panel 1 (HMMP1MAG, EMD 
Millipore, Germany) for plasma samples obtained 
at baseline (n=15), 1 month (n=13), 3 months 
(n=11) and 6 months (n=8). Briefly, 25 µl of 
undiluted plasma were loaded per well and the 
assay was run following the manufacturer’s 
instructions. The assay sensitivity for the 
different proteins was: MMP-3, 0.062 ng/ml; 
MMP-12, 0.038 ng/ml and MMP-13, 0.034 ng/ml. 
Each sample was assayed in duplicate and only 
values with a CV < 20% were accepted for the 
posterior analysis. 
Statistical analysis 
Descriptive statistics were used to define 
demographics, stroke characteristics, MMP levels 
and functional measures. Chi-square tests were 
run for categorical variables. Normality of 
continuous variables was assessed by the 
Kolmogorov-Smirnov test if N ≥ 30 or the 
Shapiro-Wilk test if N < 30. To assess differences 
between independent groups, independent 
t-tests and one-way ANOVA followed by 
Bonferroni post-hoc tests were used for normally 
distributed variables, and the values were 
expressed as the mean ± s.d., while the 
Mann-Whitney U-test was used to explore 
differences in non-normally distributed variables 
and was expressed as median and interquartile 
range (IQR). For repeated measures, Friedman 
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followed by Wilcoxon tests were used for 
non-normally distributed variables, whereas for 
variables with a normal distribution, repeated 
ANOVA followed by the Bonferroni post hoc test 
was run. Correlations between continuous 
variables were measured using the Pearson’s or 
Spearman’s coefficients, depending on their 
normality. Finally, a p value <0.05 was considered 
statistically significant. All analyses were 
completed using SPSS 15.0 software. 
 
RESULTS 
Characteristics of the stroke and control cohorts 
Table 1 shows baseline characteristics of the 
stroke rehabilitation cohort compared to controls. 
Briefly, stroke patients were significantly younger 
and had smaller body mass indexes than controls 
(p=0.008 and p=0.048, respectively). Males were 
overrepresented in the stroke group (80%) but 
not significantly. All other registered variables 
were balanced between groups. The main clinical 
variables related to the ischemic event are 
described in Table 2, which shows common 
features of the cohort of ischemic stroke 
candidates for IRT. In summary, median NIHSS on 
admission was 8 (5-12), and after 3-4 days it was 
5 (5-9), indicating an improvement (increase ≥ 4 
points) in 33.3% of the patients. Most strokes 
occurred in the carotid territory (73.3%), and 
almost half of these were classified as total 
anterior cerebral infarction (TACI, (46.7%)). Time 
from stroke onset to IRT was 11.4 ± 4.4 days. 
 
Table 1. Baseline characteristics of the control and stroke cohorts. 
 
Control Strokes P value 
 
(n=15) (n=15) 
 
Age (years) 63.5±7.6 53.9±10.6 0.008 
Gender, male 46.7 (7) 80.0 (12) 0.058 
Risk factors 
   
Alcohol 53.3 (8) 20.0 (3) 0.058 
Tobacco 13.3 (2) 33.3 (5) 0.195 
Hypertension 80.0 (12) 66.7 (10) 0.409 
Dyslipidemia 60.0 (9) 53.3 (8) 0.713 
Diabetes mellitus 26.7 (4) 20.0 (3) 0.666 
Atrial fibrillation 0 (0) 13.3 (2) 0.143 
Obesity 60.0 (9) 33.3 (5) 0.143 
Body mass index (kg/m²) 25.9±3.6 23.0±3.8 0.048 
Comorbidities 
   
Osteoarticular disorders 26.7 (4) 13.3 (2) 0.361 
Ischemic cardiopathy 0 (0) 6.7 (1) 0.309 
Psychiatric disorders 26.7 (4) 20.0 (3) 0.666 
Previous Exercise 
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Physical activity 73.3 (11) 50.0 (7) 0.196 
Physical activity (hours) 7 (0-10) 7 (0-10) 0.288 
Previous Medication 
   
Antiplatelets 26.7 (4) 20.0 (3) 0.666 
Anticoagulants 0 (0) 6.7 (1) 0.309 
Statins 33.3 (5) 33.3 (5) 1 
Antihypertensives 73.3 (11) 46.7 (7) 0.136 
Antidiabetic 20 (3) 13.3 (2) 0.624 
 
Data is displayed as mean ± SD, median (IQR) or percentage % and (number). Significant p values are 
highlighted in bold. 
 
 
Table 2: Clinical characteristics of stroke patients 
Stroke Characteristics Strokes 
  (n=15) 
NIHSS score at admission 8 (5-12) 
NIHSS motor score at admission 4 (2-7) 
NIHSS score after 3-4 days 5 (5-9) 
NIHSS motor score after 3-4 days 3 (1-5) 
Early neurological outcome    
Improvement 33.3 (5) 
Stability 53.4 (8) 
Worsening 13.3 (2) 
Etiology    
Lacunar 13.3 (2) 
Cardiopathy  33.3 (5) 
Atherothrombosis 13.3 (2) 
Others 13.3 (2) 
Unknown 26.8 (4) 
Location, Territory    
Vertebrobasilar 26.7 (4) 
Carotid 73.3 (11) 
Hemisphere of stroke   
Right 53.3 (8) 
Left 46.7 (7) 
OCSP classification    
TACI 46.7 (7) 
LACI 20.0 (3) 
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PACI 12.3 (2) 
POCI 20.0 (3) 
Symptomatic stenosis    
Extracranial 26.7 (4) 
Intracranial 20.0 (3) 
Both 6.7 (1) 
No 46.6 (7) 
Asymptomatic stenosis    
Yes 33.3 (5) 
No 66.7 (10) 
Thrombolytic therapy    
Yes 26.7 (4) 
No 73.3 (11) 
Hemorrhagic Transformation    
Yes 20 (3) 
No 80 (12) 
Time Stroke-Intensive Rehabilitation (days) 11.4±4.4 
 
OCSP: Oxfordshire Community Stroke Project; TACI: total anterior cerebral infarct, LACI: lacunar cerebral 
infarct, PACI: parcial anterior cerebral infarct, POCI: posterior cerebral infarct; Early Neurological Outcome was 
defined as improvement (increase ≥4 points in the NIHSS), worsening (decrease ≥4 points in the NIHSS) or 
stability any other change in the NIHSS. Data is shown as mean ± SD, median (IQR) or percentage % (number). 
 
Evolution of motor/functional outcomes and 
MMP levels over time 
The complete motor and functional progress of 
patients during IRT is detailed in Table 3. A 
significant improvement in the FMA, Rankin and 
BI tests had already been achieved at 1 month 
and was maintained during the complete 
follow-up period. At three months, the patients 
also showed some improvement in the FAC, 
CAHAI and 10-meter walk test. Patients showed 
minor improvements in MRC scores for the 
proximal segment of the extremities at three or 
six months.  
 
Table 3: Measures of functional/motor outcome and MMP profile 
 
Strokes    Time course     
 
Baseline 1 month 3 months 6 months 
Outcome assessment         
Fugl Meyer Assessement (0-66) 30 (6-52) 55 (14-61.5)* 60 (16-63)* 64 (26-66)* 
Modified RANKIN (0-6) 4 (3-4) 2 (1-3)* 1.5 (0-3)** 1 (0-2)* 
Barthel Index (0-100) 57 (31-83) 94 (64-100)** 100 (88.6-100)** 100 (100-100)** 
Functional Ambulation Categories (0-5) 1 (0-3) 4 (1.5-5)† 5 (5-5)* 5 (5-5)* 
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Chedoke Arm and Hand Activity Inventory 
(13-91) 
15 (13-71) 72 (13-85)† 82 (13-90) 88 (13-91) 
10 meters walk test (velocity in m/sec) 0.5 (0-1) 0.9 (0.3-1.4)† 1 (0.8-1.3) 1.1 (0.8-1.4) 
Stroke Specific Quality Of Life Scale 
(49-245) 
n.a. 168 (152.5-183) 193 (159-227) 199 (171-229)$ 
MRC Superior-Proximal (0-5) 4 (0-4) 4 (2.5-5) 5 (2-5)* 5 (4-5)* 
MRC Superior-Distal (0-5) 4 (0-4) 4 (0-5) 5 (0-5) 5 (2-5) 
MRC Inferior-Proximal (0-5) 4 (0-4) 5 (4-5) 5 (5-5)† 5 (5-5)† 
MRC Inferior-Distal (0-5) 4 (0-5) 5 (2-5) 5 (4-5) 5 (1-5) 
MMP level (ng/mL)         
MMP-3 28.2±14.8 23.6±8.8 32.5±13.4 27.7±12.3 
MMP-12 2.0±0.9 2.0±1.0 2.1±0.9 2.1±0.8 
MMP-13 4.5±1.7 4.5±2.6 4.3±1.8 4.6±2.1 
Controls         
MMP level (ng/mL)         
MMP-3 24.0±14.3       
MMP-12 2.0±0.5       
MMP-13 4.4±0.7       
 
Data is shown as mean ± s.d or median (IQR); n.a. (non available); *p<0.05, **p<0.01 and † p<0.1 vs. baseline. 
FMA (Fugl Meyer Assessement), FAC (Functional Ambulation Categories), CAHAI (Chedoke Arm and Hand 
Activity Inventory) and MRC (Medical Research Council).  
 
 
Regarding MMPs measurements, a baseline 
sample was obtained 10.7 ± 5.0 days after stroke 
onset and no correlation was observed between 
the MMP levels and the number of days after 
stroke (MMP-3: r=-0.94, p=0.761; MMP-12: 
r=0.118, p=0.688; MMP-13: r=0.296, p=0.304). 
The patients exhibited stable MMP levels during 
the whole study period, and no differences with 
controls (see table 3). Interestingly, MMP-12 and 
MMP-13 were correlated both in controls 
(r=0.925, p<0.001) and in stroke patients 
(r=0.951, p<0.001 at baseline; r=0.984, p<0.001 
at 1 month; r=0.993, p<0.001 at 3 months and 
r=0.979, p<0.001 at 6 months), but no 
relationship was found with MMP-3. 
Regarding MMP-3 in stroke patients, age was 
positively associated with higher levels at three 
and six months (r=0.676, p<0.05 and r=0.873, 
p<0.01, respectively), hypertension with higher 
levels also at 3 and 6 months (36.2 ± 11.9 vs. 16.0 
± 17.9, p<0.05 and 32.6 ± 9.5 vs. 12.9 ± 4.6, 
p<0.05) and atrial fibrillation also with higher 
levels at 3 months (49 ± 6.5 vs. 28.8 ± 11.7; 
p<0.05). At 6 months higher levels of MMP-12 
and MMP-13 were detected in dyslipidemic 
patients (2.7 ± 0.6 vs. 1.4 ± 0.4 and 6.2 ± 0.6 vs. 
3.0 ± 1.2, p<0.01 respectively). In the control 
cohort males presented higher levels of MMP-3 
(35.1 ± 13.6 vs. 14.1 ± 3.0, p<0.01) and higher 
levels of MMP-12 in subjects with diabetes (2.5 ± 
0.4 vs. 1.9 ± 0.4, p<0.05). Regarding medication, 
higher levels of MMP-12 were found in subjects 
medicated with antiplatelets, statins and of 
MMP-13 in those subjects taking antiplatelets, 
statins or antihypertensive drugs (data not 
shown). 
High levels of MMP-12 and MMP-13 are 
associated with stroke severity 
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We found a strong association between baseline 
MMP-12 and MMP-13 levels and stroke severity, 
as measured by the NIHSS score on admission 
(r=0.81 and p<0.001 and r=0.67 and p=0.008, 
respectively; see Figure 2A). MMP-12 was also 
increased in patients with higher motor scores at 
the NIHSS (r=0.625 and p=0.017). Interestingly, 
these two MMPs were elevated in patients who 
were diagnosed with a TACI and presenting the 
most extensive infarcts (p=0.009 for MMP-12 and 
p=0.058 for MMP-13 at baseline; see Figure 2B). 
No significant association were found for MMP-3 
(see Figure.2A-B), except for a statistical trend 
correlating higher levels of baseline MMP-3 with 
patients with a lower motor NIHSS score on 
admission (r=-0.514 and p=0.072). 
 
Figure 2. Association of MMP levels and baseline stroke severity and extension. A) Scatter plots 
showing significant associations between baseline MMP-12 and MMP-13 with NIHSS scores on 
admission. B) Bar graphs showing higher levels of MMP-12 and MMP-13 in patients classified as 
TACI vs. those with other classifications (LACI, PACI, POCI), according to the OSCP classification. 
 
Elevated MMP-3 and decreased MMP-12 or 
MMP-13 levels in patients with a better motor 
score during rehabilitation 
Despite the strong relationship between 
pre-rehabilitation and 6 months scores for 
several functional/motor scores (see 
supplementary Table 1), higher levels of MMP-3 
were found in the patients presenting higher 
walking velocity at one month of IRT (r=0.579 
and p=0.079). In addition, lower baseline levels 
of MMP-12 and MMP-13 were observed in 
patients who experienced a better outcome in 
the MRC upper distal extremity scale (p=0.006 
for MMP-12 and p=0.039 for MMP-13) at one 
month after or in patients who had a better 
outcome at three and six months in the lower 
proximal extremity MRC scale (p=0.026, 
respectively for baseline MMP-12 levels). These 
data are also represented in supplementary 
Figure 1. 
The best motor and functional recovery is 
associated with higher plasma levels of MMP-3 
and lower plasma levels of MMP-12 and 
MMP-13 
Our results reveal that patients with higher levels 
of MMP-3 at one month presented larger 
improvements in motor function, assessed by the 
FMA score, at the same time point (r=0.632 and 
p=0.05); this was also the case at 3 months 
(r=0.780 and p=0.013) but to a lesser extent at 6 
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months (r=0.596 and p=0.097), as shown in 
Figure 3A. Similarly, we found that higher levels 
of MMP-3 were associated with major 
improvements in the CAHAI score at three 
months (r=0.566 and p=0.07) and at the study 
end of the study (r=0.737 and p=0.037); see 
Figure 3A.  
 
Figure 3. Associations between MMP-3, MMP-12 or MMP-13 and motor recovery. A) Scatter plots 
showing a positive correlation between MMP-3 and improvement in FMA or CAHAI scores at 
different time points during the study period. B) Bar graphs showing that high MMP-3 levels one 
month after starting rehabilitation therapy predicted motor improvement assessed by MRC or FMA 
scores. C) Bar graphs showing FAC score and the 10-meter walk tests improvement in patients with 
lower MMP-3. D) Bar graphs showing elevated plasma MMP-12 and MMP-13 in patients that did 
not improve in the walking and FAC tests. 
 
During rehabilitation therapy, patients were 
grouped into those who improved and those who 
did not improve for each of the outcome 
measures in the terms defined in the Methods 
section. We confirmed our findings for MMP-3 
because stroke patients who responded better to 
rehabilitation therapy presented higher plasma 
levels of this protein at one month than patients 
who did not show improvement in the MRC of 
the upper proximal extremity (p=0.015) or in the 
MRC of the upper distal extremity score 
(p=0.014). The same results were observed for 
FMA and MRC upper proximal scores (p=0.003 
and p=0.028, respectively) at three months and 
for FMA scores at six months (p=0.003), as shown 
in Figure 3B. These results suggest the predictive 
value of MMP-3 for identifying patients who will 
respond better to rehabilitation.  
Two contradictory results connected 
improvement on the FAC score and in the 
walking test at three months with lower levels of 
MMP-3 (p=0.028 and p=0.033, respectively), as 
shown in Figure 3C. In the same line of results, 
the increase/decrease in the walking velocity at 
three and six months was inversely correlated 
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with baseline MMP-3 levels (r=-0.647, p=0.031 
and r=-0.683, p=0.02; respectively). 
Finally, plasma MMP-12 and MMP-13 were 
associated with the poorest (Figure 3D). One 
month after starting the rehabilitation program, 
we observed the highest levels of MMP-12 and 
MMP-13 in the patients that did not show an 
improved FAC score (p=0.012 and p=0.002, 
respectively) and high MMP-12 in those that did 
not show an improvement in the walking test 
(p=0.051). Moreover, higher MMP-13 at one 
month was associated with the poorest level of 
performance in the walking test at the third 
month (p=0.032). 
 
DISCUSSION 
The present study describes for the first time the 
temporal profile of plasma MMP-3, MMP-12 and 
MMP-13 up to 6 months after ischemic stroke in 
patients receiving IRT. Our results describe the 
association of MMP-12 and MMP-13 with stroke 
severity and the poorest neurological outcomes 
and identify MMP-3 as a potential molecule to 
monitor greatest improvements, suggesting that 
MMP-3 could serve as a biomarker of post-stroke 
recovery and could help in identifying those 
patients that will respond better to the 
rehabilitation therapy. 
Over the last decades, acute stroke care has 
improved, with the development of stroke units, 
hyperacute treatment with recombinant tissue 
plasminogen activator, and new thrombectomy 
strategies (18-20). However, rehabilitation 
therapies remain the only approved treatments 
for the millions of patients who each year survive 
a stroke but experience functional deficits. 
Evidence-based stroke rehabilitation care 
includes several types of health interventions, 
including early admission to specialized stroke 
rehabilitation units, intensive rehabilitation 
therapies, and task specific oriented therapies (3, 
5, 21) with the goal to help survivors become as 
independent as possible so that they can conduct 
daily living activities and achieve the best 
possible quality of life in the long-term. As we 
have reported for the stroke rehabilitation cohort 
in the present study, the most significant 
improvements are achieved within the first one 
to three months, but recovery continues for up 
to 6 months, as described (22).  
Although recent meta-analyses have shown 
strong evidence for stroke rehabilitation 
intervention (23, 24), daily practice indicates that 
individual patients respond differently to therapy, 
which raises several questions regarding which 
patients will benefit the most and which patients 
will respond better to larger and more intensive 
programs. Questions relating to the underlying 
biological mechanisms of neural plasticity that 
drive improvements in neurological functions 
remain to be answered, to known whether they 
can be therapeutically modulated to improve 
rehabilitation therapies. 
MMPs are proteolytic enzymes that can degrade 
most components of the extracellular matrix and 
remodel the pericellular space. They are 
normally expressed in most tissues and take part 
in multiple physiological processes (25). However, 
uncontrolled MMP activity is involved in the 
pathophysiology of many disorders with 
underlying inflammation processes. In cerebral 
nervous system-related diseases, some MMPs 
have been associated with neurodegeneration, 
demyelination, neurotoxicity and blood brain 
barrier dysfunction (26, 27), but emerging 
evidence has positioned these proteases as key 
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players in tissue regeneration processes, 
including post-stroke repair (8, 26). To our 
knowledge, our study shows the longest 
temporal profile of MMP levels in stroke patients: 
from the sub-acute to the chronic phase. 
Plasma MMP-3, MMP-12 and MMP-13 remained 
stable over time without major fluctuation but 
with two opposite behaviors. In the current study, 
elevated baseline MMP-12 and MMP-13 levels 
were found in patients who had more severe 
infarcts, whereas MMP-3 remained independent 
of stroke characteristics. Previous results from 
our group have described the expression of 
nuclear MMP-13 in neuronal cells after ischemia, 
where it is acutely elevated in the infarct tissue 
(28, 29). In another study, we reported the role 
of MMP-13 as a plasma biomarker for lesion 
expansion, as measured in diffusion-weighted 
images in the first days following stroke (30). 
With regards to its function as a major 
collagenase, other authors have shown that 
MMP-13 expression is increased in the 
BBB-damaged vessels of spontaneous 
hypertensive rats (31). These data support our 
finding that higher baseline MMP-13 levels are 
related to infarct extension and stroke severity. 
However, other investigations have reported the 
activation of MMP-13 by two weeks after 
ischemiareperfusion, which is associated with 
perineuronal matrix remodeling (32) and 
suggests its role in neuronal remodeling. Less is 
known about MMP-12, which is also named 
macrophage elastase. In an experimental 
hemorrhagic stroke model, MMP-12 expression 
was associated with poor functional recovery of 
forelimb function and with the development of 
secondary injury (33). More recently, the specific 
knockdown of MMP-12 by the administration of 
a shRNA-expressing plasmid (silencing the gene) 
resulted in brain neuroprotection in a rat model 
of transient ischemia via MMP-9 downregulation 
(34). Again, published studies have related brain 
MMP-12 expression with larger infarct size and 
worse neurological outcome, which is in 
agreement with our results. 
Finally, the most striking results of our study are 
related to plasma MMP-3, a member of the 
stromelysin sub-family that degrades multiple 
extracellular matrix components, activates 
growth factors and cleaves adhesion molecules, 
among other functions (26). We demonstrate, for 
the first time, an association for MMP-3 not only 
with better neurological status but also with 
improved motor recovery at later time points 
during rehabilitation therapy. Importantly, 
baseline MMP-3 levels were not related to stroke 
characteristics nor were they correlated with 
baseline motor/functional prerehabilitation 
scores. On the other hand, when assessing 
improvement during the follow-up using the 10 
meter walk test we observed contradictory 
results. Here we could speculate that important 
achievements such as better stability could not 
translate into higher walking velocity. MMP-3 
also, like other MMPs, plays a dual 
detrimental/remodeling role, and an extensive 
literature supports its central position in brain 
tissue embryonic and postnatal development, in 
addition to its involvement in axonal extension, 
synaptic plasticity and remyelination (26, 35). 
Experimental models of stroke have shown that 
MMP-3 expression is critical for intracranial 
bleeding after tPA administration (36) and for 
perineuronal agrin cleavage after 
ischemiareperfusion in rats (37). Interesting 
results how a single administration of a broad 
spectrum MMP inhibitor (GM6001) after 
ischemia, by protecting BBB integrity acutely, 
enhanced vascular remodeling at three weeks 
related to increased MMP-3 and tight junction 
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expression (38).  
The use of biological samples to detect the 
presence of specific molecules with the aim of 
monitoring ongoing pathophysiological processes 
and predicting neurological outcomes for stroke 
survivors is the focus of current clinical and 
experimental research (39, 40). However, very 
few studies have investigated the use of 
biomarkers during rehabilitation therapy. Blicher 
and colleagues studied the neurotransmitter 
GABA by magnetic resonance spectroscopy in 
relation to motor function after 2 weeks of 
constrained-induced movement therapy and 
showed an association between the extend of 
motor improvement and the magnitude of the 
GABA/creatine ratio (41). A second study recently 
reported the use of 8-hydroxy-2’-deoxyguanosine 
(8-OHdG), a sensitive biomarker for oxidative 
DNA damage that is detectable in urine samples, 
in a cohort of stroke patients undergoing 
rehabilitation therapy (42). The authors reported 
a negative correlation between FMA scores and 
8-OHdG levels after rehabilitation treatment and 
lower levels of baseline in patients that exhibited 
more improvement in motor function, suggesting 
the use of 8-OHdG as a biomarker of stroke 
recovery.  
Nonetheless, several caveats of this study should 
be discussed. First, our study does not provide a 
control cohort of stroke patients with similar 
characteristics that did not receive IRT to 
determine the exact effect of rehabilitation 
therapy on MMP levels. However, this is for the 
understandable reason that ethical principles 
demand that all patients admitted at our hospital 
who are candidates for receiving IRT must be 
enrolled in the program. In addition, the lack of 
power due to the number of patients did not 
allow us to perform multivariate analysis to 
explore possible interactions between the clinical 
variables and the biomarkers. The designing of 
future multicenter studies will overcome this 
limitation and allow a more detailed analysis. 
 
CONCLUSIONS/IMPLICATIONS 
The ability to monitor stroke recovery using 
biomarkers would be of great help when making 
decisions related to a patient’s management and 
rehabilitation programs. To our knowledge, this is 
the first report on ischemic stroke patients who 
were enrolled to IRT to describe the temporal 
profile of plasma MMPs over a 6-month 
follow-up period, and we show exciting results 
regarding the association of MMP-3 with the best 
motor recovery. This observation could be 
related to the role of MMPs in brain plasticity 
and tissue regeneration. Regardless of the 
preliminary nature of our study and the need to 
design larger studies in a multi-center setting, we 
can conclude that MMPs have emerged as 
potential biomarkers of recovery during 
rehabilitation therapy following stroke. 
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Supplementary Table1. Association study between pre-rehabilitation and 6 months scores of functional and motor measures. 
                            
  RANKIN FMA CAHAI WALKING SS-QOL MRC (Upp-Prox) MRC (Upp-Dis) MRC( Inf-Prox) MRC (Upp-Dis) 
  r  r  r  r  r  0-4 5 0-4 5 0-4 5 0-4 5 
NIHSS           
(admission) 
  -0.55†               14.5 (12-17) 7 (4.5-8.5)*     
NIHSS 
motor 
(admission) 
                  7.5±0.7 3.0±2.6*     
NIHSS                               
(3-4days) 
0.723** -0.678* -0.568†     10.5 (8.3-13.5) 5 (4-7)* 10.5 (8.3-13.5) 5 (4-7)* 13 (12-14) 5 (4.5-8.5)* 12 (8-14) 5 (4.3-8.5)* 
NIHSS 
motor                   
(3-4days)  
0.586* -0.797** -0.67* -0.597† -0.812** 5.5±2.6 2.1±2.2* 5.5±2.6 2.1±2.2* 7.5±0.7 2.4±2.1* 6.7±1.5 2.1±2.0** 
RANKIN  0.835** -0.681* -0.575† -0.681* -0.592† 4 (4-4) 3 (3-4)* 4 (4-4) 3 (3-4)*     4 (4-4) 3 (3-4)† 
BI  -0.871** 0.888** 0.745** 0.603* 0.670* 36 (18.3-41) 79 (62-95)* 36 (18.3-41) 79 (62-95)* 22.5 (14-31) 70 (41-89)† 31 (14-41) 74.5 (46.3-92)* 
FMA  -0.707* 0.841** 0.784** 0.528† 0.602† 4 (2.5-6.3) 50 (23-55)* 4 (2.5-6.3) 50 (23-55)* 3 (2-40) 47 (6.5-54)* 4 (2-4) 48.5 (11-54.5)* 
FAC  -0.836** 0.789** 0.674* 0.765** 0.696* 0 (0-0.8) 3 (1-5)* 0 (0-0.8) 3 (1-5)* 0 (0-0) 2 (0.5-4.5)† 0 (0-0) 2.5 (1-4.8)* 
CAHAI  -0.612* 0.875** 0.876**     13 (13-13) 70 (13-71)* 13 (13-13) 70 (13-71)*     13 (13-13) 68.5 (13-71)† 
WALKING  -0.791** 0.711* 0.58† 0.813** 0.879** 0 (0-0.4) 1 (0.5-1)* 0 (0-0.4) 1 (0.5-1)* 0 (0-0) 0.5 (0.3-1)† 0 (0-0) 0.8 (0.5-1)* 
MRC  
(Upp-Prox)  
-0.536† 0.860** 0.879**     0 (0-0) 4 (4-4)** 0 (0-0) 4 (4-4)**     0 (0-0) 4 (4-4)* 
MRC  
(Upp-Dis) 
  0.690** 0.593†                     
MRC  
(Inf-Prox) 
-0.566†   0.609* 0.548† 0.673* 1 (0.3-3.3) 4 (4-5)* 1 (0.3-3.3) 4 (4-5)*     0 (0-1) 4 (4-5)* 
MRC  
(Inf-Dis) 
  0.571†   0.588† 0.732*         0 (0-0) 4 (2-5)† 0 (0-0) 4.5 (4-5)* 
  
 
Note: ** p <0.01, *p <0.05 and † p<0.1 
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Supplementary Figure 1. MMP levels and motor scores during rehabilitation. A) Correlation plot 
showing the association between MMP-3 levels and the walking velocity assessed at 1 month. B) Bar 
graphs showing the difference in baseline MMP-12 and MMP-13 levels between patients that showed 
normal or weakened muscle strength at different time points assessed by the MRC score. 
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4.  Discussion   
 
4.1. MMP-13 deficiency protects mice from ischemia-reperfusion injury whereas 
high level of plasma MMP-12 or -13 is associated with stroke severity in 
ischemic stroke patients. 
The present study firstly demonstrates that MMP-13 participates in acute damage 
which is enhanced during the reperfusion phase in a mouse model of stroke and 
related to the presence of spontaneous HT. In parallel we have described for the first 
time the association of MMP-12 and MMP-13 with stroke severity and with the 
poorest neurological/motor outcomes in patients under neurorehabilitation therapy. 
It is known that ischemic damage induces the unregulated expression of several 
MMPs at multiple levels (brain and plasma), which has been documented previously 
both in humans and rodent models of cerebral ischemia71,123,124,125. Most of these 
papers focus on MMP-9, a gelatinase that has been extensively studied in the 
ischemia context, by proving that its gene or pharmacological inhibition protects 
from ischemia injury and reduces hemorrhagic transformations123,126,127. However we 
know that other MMPs are also dysregulated in the human infarct tissue suggesting 
its implication in tissue damage. In this regard a previous study from our group 
showed that several members of the MMP-family of proteases, including MMP-9 and 
-13 among others, were upregulated in the post-mortem infarct tissue of patients 
who had an ischemic stroke within the previous 4 days when compared to the 
contralateral hemisphere81. Furthermore, it is known that MMP-9 is able to be 
activated directly after stroke onset, with the plasma level correlated with the infarct 
size and functional outcome87,128 , while only a few studies shows the MMP-13 
activation in the brain/plasma related to lesion expansion in the acute phase101,102. 
More recently, increased MMP-13 mRNA and protein levels were observed in brain 
tissue during the acute phase in a rodent model of ischemia-reperfusion129.  
The two primary outcomes in preclinical studies are infarct lesion reduction and the 
improvement in neurological function which might translate to an improved 
neuroprotection or functional outcome clinically. The quantification of infarct size 
can be obtained by several methods such as TTC staining for experimental models or 
MRI for either animal or human subjects. However, more variability exists on the 
tests used to assess functional status or neurological outcomes in 
rodents130,131,132,133,134, whereas in humans, the NIH stroke Scale score and the 
modified Rankin scale being the gold standard methods to evaluate stroke severity 
and functional outcome135,136,137, respectively. 
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Our results show a significant reduction on infarct size in MMP-13 gene knock-out 
(KO) mice compared to wild-type (WT) at one and three days after cerebral 
ischemia-reperfusion, but not after permanent MCAo although infarct volumes were 
also smaller in MMP-13 deficient mice. In fact, differences between the two models 
were observed in the WT groups, being infarcts of the ischemia-reperfusion model 
larger than in the permanent occlusion but not significantly. 
The observed neuroprotection in terms of infarct volume was correlated with our 
observation on the reduced incidence of spontaneous HT events in MMP-13 KO mice. 
Spontaneous HT occurs in patients with ischemic stroke mainly between the 3th and 
the 7th day of stroke onset138, and the disruption of BBB is a central step that 
precedes HT development. Early within the first 2 hours, the opening of BBB has 
been observed in stroke patients and enhanced in later phases139. In the delayed HT, 
the opening of BBB is thought to be mediated by MMPs, other brain proteases, 
neuroinflammation, as well as vascular remodeling and neovascularization30. It has 
been described that MMPs derived from blood have a dominant role in the early BBB 
disruption and HT, while the brain derived MMPs such as MMP-9, MMP-2 and 
MMP-3 contribute to the delayed HT140,141,142. Related to endogenous neurorepair, 
we have explained that vascular remodeling and angiogenesis are important for the 
recovery after stroke143, and pro-angiogenic factors may also promote post-stroke 
HT144,145. For example, VEGF is an important factor involved in angiogenesis and a 
decrease on VEGF reduces HT in rodent stroke model146. 
Our results show a tendency to an increased incidence of hemorrhage at day 3 which 
might indicate the involvement of MMP-13 in the delayed HT. Although HT is 
associated with the size of ischemic area147, our study seems to be independent to 
this fact since similar infarct size were observed at 24 hours and 72 hours after 
ischemia-reperfusion in WT mice who increased the incidence of HT at 72 hours. At 
the same time, no such increase was found in MMP-13 KO mice, indicating that 
MMP-13 deficiency may protect the mice brain tissue not only from initial tissue 
injury but also from the upcoming hemorrhage. Regardless the day of euthanasis, 
WT mice presented increased incidence of HT events than MMP-13 KO mice.  
We have also observed the decreased amounts of brain angiogenic factors including 
VEGF and Ang-2 in MMP-13 KO mice at day 7 after ischemia. The combination of 
VEGF and Ang-2 has been demonstrated to lead angiogenesis related to BBB 
disruption by increasing the activity of MMP-9 after 2 weeks treatment in mice148. 
The biphasic role of VEGF in stroke has been described in a previous study with early 
VEGF promoting HT and later VEGF promoting BBB integrity and vessel function149. 
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With this background, MMP-13 may also play a similar dual role directly and 
indirectly in HT in the first 7 days after stroke. 
One unexpected finding is the presence of striatal infarctions at day 3 after 
ischemia-reperfusion, related to the presence of hemorrhage within the infarct area. 
Since our model or MCA occlusion only affects the cortical territory, we hypothesize 
that the growing formation of a hematoma induced by the hemorrhage may constrict 
the vascular supporting blood flow to striatum. Unfortunately, most studies based on 
neuroprotection assess infarct size and extension at 24-48 hours making difficult to 
compare this finding with others. 
However, our study also includes a longer time follow-up of the mice to study 
neurorepair mechanisms, and it seems that the final functional outcome at day 14 
was not different between MMP-13 KO and WT mice which presented larger infarcts 
and more incidence of HT events acutely (although these observations are 
performed in separate study groups). This could suggest that WT mice have 
repaired/recovered better or faster than that in MMP-13 deficient mice and our next 
findings support this hypothesis.  
The other primary outcome mentioned at the beginning of this section is the 
functional outcome. In this regard, the appropriate tests should be chosen accurately 
according to the stroke models, evaluation time and animal species even strains130. 
The grip strength test is highly specific, well-defined aspect of behavior and less 
stressful to the animals than other tests. KIlic et al. found that grip test is sensitive for 
detecting outcomes from different treatments in C57BL/6 mice after mild transient 
ischemia at day 7 as well as day 30150. In our hands, a significantly reduced forelimb 
force was also found from day 1 until day 14 in permanent distal MCA occluded 
Balb/c mice130. In the present study, the grip strength test has proven to detect 
reduced forelimb function after transient MCAo in C57BL/6 mice as long as 14 days 
after ischemia. At day 1, all mice decreased the forelimb force however this decrease 
was only significant in WT mice, in agreement with our findings on infarct volume 
and HT incidence. During the follow-up only the decreased forelimb force in WT 
versus MMP-13 KO was maintained at one week but not at two weeks. This fact 
could indicate different repair mechanisms between genotypes. 
It is interesting to link the MMP-13 observation in the animal model of ischemia with 
the findings in patients under rehabilitation therapy after stroke: high levels of 
MMP-13 were observed in those patients with more extensive infarcts (TACI 
classification) and presenting a more severe neurological status at baseline 
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(measured by the NIHSS). Although blood samples were obtained in some cases days 
after the baseline neurological evaluation no association was found between plasma 
MMP levels and the day of baseline blood sampling. The expression of MMP-13 is 
increased in the BBB-damaged vessels of rats151, and the role of plasma MMP-13 as a 
biomarker for the lesion expansion has been proposed in a previous study from our 
group102. Together with our finding in the experimental model, we can conclude that 
MMP-13 contributes to the acute cerebral damage further contributing in BBB 
damage. It would have been interesting to analyze the association of MMP-13 level 
with the presence of spontaneous HT, however the sample size was too small to 
speculate on this interesting point that certainly deserves to be further investigated. 
Overall, we demonstrate the role of MMP-13 in brain injury after ischemia however 
our group and other have reported the active role of other MMPs related to brain 
infarcts, as detailed in the introduction section. Therefore, which MMP is more 
important? Are these MMP actions related? 
The activation of MMP proteins by other members of the family has been widely 
described152,153. We have studied the protein levels of infarct MMP-3, -8 and MMP-9 
compared to their contralateral hemisphere describing a significant increase at day 3 
after ischemia in both genotypes, with a significant decrease of all studied MMPs in 
the ipsilateral hemisphere of the MMP-13 KO mice compared to WTs. In our study, 
the detection of MMPs was designed to measure the total amount of MMPs 
including pro and activated forms except for MMP-9 (only the pro-form) due to 
manufacturer setting of the kit. We included one collagenase (MMP-8), one relevant 
gelatinase as MMP-9 and one stromelysin (MMP-3) as representative proteins of the 
MMP family that could undergo compensatory, up- or down- regulations in the 
knockdown model of MMP-13. 
Our conclusion is that the decreased level of MMP-3, -8 and pro-MMP-9 in MMP-13 
KO mice in the context of cerebral ischemia indicates that the interaction of MMP-13 
with other members of MMPs family might be controlling the MMP cascade. MMP-8 
is known as the “neutrophil collagenase” targeting primary fibrillar collagen which is 
upregulated in the infarct tisue81. In our study, the knockdown of MMP-13 does not 
stimulate the overexpression of MMP-8, instead inhibits the expression of this 
collagenase after ischemia indicating the possible central and upstream role of 
MMP-13. In the present study, we may conclude that MMP-13 deficiency affects the 
expression of MMP-9, and this gelatinase has been directly involved in both injury 
and repair mechanisms after stroke71,76. In a previous study from our group both 
MMP-9 and MMP-13 showed an association with infarct lesion expansion after 
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stroke in a multiple screening protein array of the MMP family102. Other studies have 
demonstrated that the knockdown of MMP-12 inhibited the increased MMP-9 
activity in ischemic brain154 suggests that the interaction among MMPs in the 
ischemia context is possible.  
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4.2. MMP-13 deficiency inhibits spontaneous neurorepair by reducing the number 
of proliferating neuroblasts and angiogenesis in peri-infarct areas, while 
decreased level of plasma MMP-12 or -13 is associated with better motor 
recovery in patients. 
This thesis shows how the deficiency in MMP-13 reduces the amount of newly born 
neuroblasts in the peri-infarct areas during neurological recovery and alters 
stroke-induced angiogenesis by reducing peri-infarct vessel density and suppressing 
the amounts of G-CSF, Ang-2 and VEGF-A after cerebral ischemia. In stroke patients, 
high MMP-12 and -13 levels during rehabilitation were found in patients with a worst 
recovery, however those levels were found associated to stroke severity at baseline. 
We have learnt that the regulation of MMPs during post-stroke might promote a 
therapeutic effect71 at both acute and stroke repair phases, and most therapeutic 
approaches under investigation now focus on the enhancement of endogenous 
repair mechanisms such as neurogenesis and angiogenesis155. In our experimental 
ischemia study, a similar cortical atrophy and functional outcome were observed 
among genotypes at day 14 after ischemia, which could be a balanced consequence 
of both the inhibition of cell apoptosis and/or promotion of post-stroke repair 
mechanism. We prove that as least angio-neurogensis progression is altered in mice 
lacking MMP-13.  
Our results show a significant reduction in the number of proliferating neuroblasts 
(BrdU+/DCX+ cells) migrated from the SVZ towards to the peri-infarct cortex in 
MMP-13 KO mice at day 14 after stroke, despite the total amount of neuroblasts in 
those areas did not change among genotypes. We explored if new mature neurons 
were generated in those areas but numbers were similar among genotypes. In this 
regard, a study focused on toll-like receptor 4 in focal cerebral ischemia model 
described some BrdU labeled cells in the peri-infarct cortex co-stained with an 
interneuron marker at day 14, indicating that the new generated neuroblasts after 
stroke were able to maturate into neurons156. In the same line, Saha et al. found that, 
only a few number of proliferating cells present in areas surrounding the lesion 
expressed NeuN, while most of them co-express GFAP and Olig2157. Therefore, it 
seems possible that other neuronal cells or progenitors could be under proliferation 
in our peri-infarct tissue.  
Importantly, a positive association between the number of proliferating neuroblast 
and vessel density was observed in the present study. Neurogenesis has been shown 
to be coupled to angiogenesis in a post-stroke neurovascular niche158. Other authors 
have also identified that the proliferating neuroblasts in peri-infarct areas are closely 
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associated to the blood vessels159. The mechanism underlying this crosstalk may 
involve the vascular network acting as migration scaffolds as well as being the source 
of pro-neurogenic and migratory factors such as VEGF and SDF-1160. Delayed 
inhibition of SDF-1 at day 7 suppresses neovascular remodeling and impairs 
functional recovery at day 1493.  
In line of these studies we have observed smaller vessel density in ipsilateral 
peri-infarct tissue of MMP-13 KO mice compared to WTs at 14 days, but not at day 7 
post-ischemia. However, we found a suppressed amount of thropic factors in 
MMP-13 KO mice at day 7, such as VEGF-A, G-CSF and Ang-2, which occurs prior to 
the observation of decreased vascular density. Additionally, these factors may 
contribute to the recovery after ischemia damage: VEGF-A is one of the VEGF family, 
which plays multiple roles in the normal adult brain, including vascular homeostasis, 
neurogenesis, synaptic plasticity and neuronal activity161 and similar functions have 
been found after pathological stimuli162. VEGF-A protein expression increases in 
neurons, astrocytes and macrophages after ischemia in rats163. At 24 hours after 
MCAo in rats, intraventricular administration of VEGF-A for 3 days increased the 
post-ischemic BrdU labeling in neuronal cells as well as immunoreactive endothelial 
cells 164. What’s more, the effect of a cell-based therapy aiming to enhance 
post-stroke functional recovery could be enhanced by the combination with VEGF-A 
in several MCAo models162. G-CSF is a hematopoietic growth factor produced by 
activated monocytes as well as endothelial cells, fibroblasts, mesothelial cells and 
platelets165,33. G-CSF and its receptors are expressed in response to ischemia in the 
penumbral region of ischemic stroke, and markedly improve long-term behavioral 
outcome166. The up-regulated expression in the subacute phase has been proven 
predominantly in vascular cells167 and the G-CSF administration after tMCAo 
enhances angiogenesis as well as neurogenesis at day 7 after ischemic brain injury in 
rats168. Additionally, Ang-2 is typically expressed at sites of vascular remodeling in the 
adult tissue, which is dramatically increased in the infarct cortex and maintained for 
as long as 7 days after ischemia in mice169,170. The combination of VEGF and Ang-2 
promotes more angiogenesis at 2 weeks after treatment in the adult mice brain 
compared to VEGF alone148. Besides, Ang-2-enhanced migration and neuronal 
differentiation of SVZ neural progenitor cells at day 7 after MCAo in mice; while 
Ang-2 enhanced migration could be blocked by matrix metalloproteinase inhibitor171. 
Finally, EPCs involved in vascular remodeling after ischemia have been proven to 
secrete a combination of these factors including fibroblast growth factor (FGF-b), 
platelet-derived growth factor (PDGF-bb) and VEGF, among others122. FGF has shown 
to reduce the infarct volume in ischemic rats in the subacute phase, which may 
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involves post-stroke angiogenesis and neurogenesis172,173. The expression of PDGF is 
upregulated in neurons, reactive astroglial cells and pericyte after ischemic stroke in 
humans and animals174,175, and the platelet microparticles containing VEGF, FGF and 
PDGF significantly promote neural stem cell proliferation, survival and differentiation, 
which can be partly blocked by any specific inhibitor176. 
Whether the decreased neurogenesis in MMP-13 KO mice was finally caused by the 
direct actions of MMP-13 or by the relatively smaller infarct size was not fully 
addressed in the present study. A strong negative correlation between cell 
proliferation at the ipsilateral SVZ at day 14 and the infarct size at day 2 has been 
reported in a filament induced permanent MCAo model156, while other studies have 
demonstrated that MMP-9 directly contributes to the increased neuroblast migration 
after stroke, with MMP-3 being involved in the neural progenitor cells’ migration94,89. 
In this line we have shown results on suppressed expression of MMP-3 and -9 in the 
MMP-13 KO genotype which could explain a modulation on neuroblast migration. 
However, in stroke patients, we have observed an association between decreased 
level of plasma of MMP-12 and -13 with better motor recovery during rehabilitation 
assessed with the MRC and FAC scores. This is possibly related to the relatively high 
baseline MMP-12/-13 levels in patients with more severe and extensive strokes. The 
statistical adjustment for baseline stroke severity and other factors such as age may 
solve this issue, but as explained larger studies increasing the sample size are 
needed.    
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4.3. MMP-13 gene silencing impairs the angio-vasculogenic function of 
Endothelial Progenitor Cells which shape simpler and less connected vascular 
networks in vitro. 
As discussed we have demonstrated that MMP-13 deficiency impairs spontaneous 
vessel formation in vivo in the peri-infarct cortex at day 14 after cerebral ischemia in 
mice. In the context of tissue repair, this fact could depend on the capability of 
endogenous EPCs actions during vessel remodeling. In this regard, we also show that 
silencing the MMP-13 gene impairs the EPCs’ function on tubulogenesis in Matrigel 
assays in vitro, indicating the key role of this protease in vessel formation.  
Nowadays more evidences show that EPCs are present after ischemic stroke since 
the first study of EPCs mobilization in response to tissue ischemia177. The 
maintenance of endothelial integrity plays a critical role in vascular-related diseases 
and EPCs have been shown to be incorporated into neovessels63,178. Taguchi et al. 
firstly reported that CD34þ/CD133þ cells, as a EPCs-enriched population, provided a 
marker of cerebrovascular function179. And several studies have proven that 
endogenous EPCs participate in the neovascularization via CXCR-4/SDF-1 axis after 
permanent MCAo in rats180.  
After stroke injury, it is known that there is a modulation on circulating EPCs level 
which produce a variety of growth factors as well as cytokines or chemokines 
including FGF, VEGF, PDGF-bb, CXCL4, CXCL7 or several MMPs122,181,182,183, these 
factors might stimulate local endothelial cell mobility, growth and fucntion112 and 
other repair mechanisms such as neurogenesis or oligodendrogenesis as discussed in 
the EPCs’ review publication155. In this regard the first observations after EPCs 
identification suggested that these cells contributed to neovascularization by 
differentiating into cells forming structural components of the vasculature63,177,184. 
However the paracrine hypothesis that EPCs contribute to vascular growth primarily 
by secreting proteins and recruiting additional progenitor/stem cells to the injury site 
has become more acceptable185,186,187. 
MMPs play a key role in the degradation of basal membrane, one of the earliest steps 
of new vessel formation during angiogenesis or vasculogenesis. MMP-13 acts as a 
collagenase by cleaving the interstitial collagens (I, II, and III) and has a key role in the 
MMP activation cascade188. The angio-vasculogenic response of EPCs has been 
reported to be impaired in MMP-9 deficient mice in an MCAo model95,126 and in a 
hindlimb ischemia model189. In this context, we demonstrate for the first time the 
role of MMP-13 on EPCs function in an in vitro model of tube formation. The 
outgrowth endothelial cells (OECs) used in the present study are a homogenous and 
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highly proliferating cell population of endothelial-like cells which directly participate 
in tubulogenesis190, while endothelial cells proliferation can be stimulated by the 
EPCs secretome191. Thus, the final in vivo influence of MMP-13 on endogenous or 
therapeutic EPCs function will influence not only the direct impairment of vessel 
formation, but also to the secretion of angiogenic/trophic factors. However, whether 
the in vitro tubulogenesis findings could translate into the in vivo setting of vessel 
formation stimulated by EPCs is still unknown.  
  
Discussion  
97 
 
4.4. Elevated plasma MMP-3 is associated to motor and functional improvement 
during rehabilitation therapy after stroke. 
We have described for the first time the temporal profile of several MMPs over 
different time points in patients under an intensive neurorehabilitation program up 
to 6 months identifying MMP-3 as a potential monitoring molecule to detect those 
patients that will respond better to rehabilitation therapy. 
The use of biological samples to detect the presence of specific molecules with the 
aim of monitoring ongoing pathophysiological processes and predicting neurological 
outcomes for stroke survivors is the focus of current clinical and experimental 
research192,193. However, very few studies have investigated the use of biomarkers 
during rehabilitation therapy as explained in the introduction section and none has 
explored the use of MMPs. 
Why studying a biomarker for recovery in the context or neurorehabilitation?  
The daily practice for physiatrists indicates that individual patients respond 
differently to therapy, which raises several questions regarding which patients will 
benefit the most from the proposed program or which patients will respond better to 
larger and more intensive programs. Moreover, it is accepted that rehabilitation 
enhances neural/brain plasticity but no pharmacological treatments are available to 
modulate or enhance this plasticity111. With this aim it is imperative to identify the 
underlying biological mechanisms of neural plasticity that drive improvements in 
neurological functions. 
To know the temporal profile of a given molecule (such as MMPs) in circulating blood 
could provide us an amazing chance to develop its use as a biomarker to diagnose or 
predict the patient outcome. For example, plasma MMP-9 level within acute (<24 - 
48 hours) phase of ischemic stroke has proved to correlate with severe outcome, 
large infarcts and has been considered as a biomarker for acute hemorrhage after 
ischemic stroke194,195,196. However, several promising markers have not finally shown 
sufficient evidence to support the use of any of them in the clinical practice197 for 
several reasons (the source of plasma MMPs may differ from that of MMPs in brain, 
a single marker may not be able to reflect the complexity of a neurorepair process, 
etc.).  
MMP-3, also known stromelysin-1 presents a broad substrate specificity for 
extracellular matrix proteins including fibronectin, collagen, lamina and 
proteoglycans, as well as for other proteases including pro-MMP-3, -8, -9 and 
-13198,199. Neuroscience literature supports its central position in brain tissue at 
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embryonic and postnatal development, in addition to its involvement in axonal 
extension, synaptic plasticity and remyelination199,200. Moreover, experimental 
models of stroke have shown that MMP-3 expression is critical for intracranial 
bleeding after tPA administration201 and for peri-neuronal agrin cleavage after 
ischemia-reperfusion injury in rats202 while the single administration of a broad 
spectrum MMP inhibitor (GM6001) after ischemia protected BBB integrity acutely 
and enhanced vascular remodeling related to increased tight junction expression203. 
Our study on MMPs as potential markers of functional response to rehabilitation 
therapy describes an association of MMP-3, for the first time, with better 
neurological status at one month but also with improved motor recovery at later 
time points during rehabilitation therapy. Importantly, MMP-3 baseline level was not 
associated to stroke severity measured by NIHSS, extensive infarcts, age or other 
factors that could compromise the final outcome of the patient. Although the 
reduced number of patients studied did not allow us to perform multivariate analysis 
to explore possible interactions between the clinical variables and the proposed 
biomarkers. 
We have found similar levels between patients and controls and no change over time 
in MMP-3 levels, however those patients that showed better improvements in the 
FMA, MRC and CAHAI scores presented higher levels of MMP-3. Those tests are 
widely used and accepted to monitor motor/functional status and progression in 
rehabilitation programs204. In this line another publication has shown the potential 
use of 8-OHdG (a promising biomarker of oxidative stress) as a valid predictor of 
functional outcomes in patients under rehabilitation after stroke by using the FMA 
and MRC scores205. 
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4.5. Future perspectives 
Our results show the protective actions of MMP-13 deficiency in terms of infarct 
volume and hemorrhagic transformation which deserves further confirmatory 
studies such as a the specific pharmacologic in vivo inhibition of MMP-13 together 
with potential recovery studies in MMP-13 KO mice by administrating recombinant 
MMP-13. Also, confirmatory studies in other MCAo models will provide further 
evidences of our findings.  
The in vitro tubulogenic remodeling study has demonstrated the promising role of 
MMP-13 in angiogenesis, but how will it modulated EPCs performance in vivo is still 
unknown. Since EPCs are being proposed as advanced therapies for stroke repair, 
new research is needed to relate the current in vitro observations to the in vivo 
context of cerebral ischemia in a putative EPC treatment.  
Finally since MMP-13 is known to activate other MMPs such as MMP-2 and MMP-9 
and we have demonstrated the important role of MMP-9 in EPCS function in other 
studies, it could be possible that the actions described for MMP-13 are up-stream in 
a proteolitic cascade. Additional studies investigating the consequences of MMP-13 
activation/inhibition within the MMP family would provide valuable information to 
identify future therapeutic targets. 
A multicentre study is needed to confirm our findings on MMP-3 as potential marker 
to monitor motor progression during rehabilitation therapy, which potentially could 
be used to adjust and adapt rehabilitation programs for stroke patients.  
Finally to better translate our results into clinical studies, the use of aged MCAo 
models, studies in female rodents or in mice carrying stroke co-morbidities are 
needed since functional outcome, neuroblast migration, vascular remodeling and the 
brain plasticity response might be influenced by those factors. 
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5.  Conclusions 
 
 
The main conclusions of this PhD thesis are:  
 
1) EPCs secretome contribute to post-stroke re-vasculatrization by mediating 
cell-cell communication actions. These interactions connect angiogenesis but 
also neurogenesis and oligodendrogenesis within a dynamic neurorepair niche.   
 
2) MMP-13 is a crucial protease involved in both the development of acute infarct 
lesions after cerebral ischemia as well as vascular remodeling and neurogenesis 
in late phases by controlling the protein expression of other brain MMPs and 
trophic factors such as G-CSF, Ang-2 and VEGF-A. High levels of plasma MMP-13 
as well as MMP-12 are associated with stroke severity in patients.  
 
3) We firstly report the temporal profile of plasma MMP-3, MMP-12 and MMP-13 
during rehabilitation therapy and demonstrate the potential use of MMP-3 as a 
biomarker of motor improvement. 
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